


Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer

Graphical abstract



Authors

Meisam Bagheri, Gadisti Aisha Mohamed, Mohammed Ashick Mohamed Saleem, ..., Scott A. Gerber, Todd W. Miller, Diwakar R. Pattabiraman

Correspondence

tomiller@mcw.edu (T.W.M.), diwakar.r.pattabiraman@dartmouth.edu (D.R.P.)

In brief

Bagheri et al. demonstrate that the FDA-approved microtubule inhibitor eribulin, when applied in the treatment-naive setting, induces epigenetic remodeling to reverse the epithelial-to-mesenchymal transition, prevent metastasis, and sensitize breast cancer cells to other chemotherapeutics. These findings suggest that the order of exposure to chemotherapeutics can shape cancer cell biology.

Highlights

- FDA-approved drug eribulin induces ZEB1-SWI/SNF-directed chromatin remodeling
- Remodeling drives mesenchymal-to-epithelial transition in triple-negative breast tumors
- Eribulin sensitizes triple-negative breast cancer cells to other chemotherapeutics



Article

Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer

Meisam Bagheri,¹ Gadisti Aisha Mohamed,¹ Mohammed Ashick Mohamed Saleem,² Nevena B. Ognjenovic,¹ Hanxu Lu,¹ Fred W. Kolling,³ Owen M. Wilkins,³ Subhadeep Das,² Ian S. LaCroix,¹ Shivashankar H. Nagaraj,^{4,5} Kristen E. Muller,⁶ Scott A. Gerber,¹ Todd W. Miller,^{1,7,8,9,10,*} and Diwakar R. Pattabiraman^{1,9,*}

¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

²Lifeytes India Pvt. Ltd., Bengaluru, India

³Center for Quantitative Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

⁴Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia

⁵Translational Research Institute, Brisbane, QLD 4102, Australia

⁶Department of Pathology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

⁷Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA

⁸Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA

⁹These authors contributed equally

¹⁰Lead contact

*Correspondence: tomiller@mcw.edu (T.W.M.), diwakar.r.pattabiraman@dartmouth.edu (D.R.P.)

<https://doi.org/10.1016/j.xcrm.2024.101504>

SUMMARY

Targeted therapies have improved outcomes for certain cancer subtypes, but cytotoxic chemotherapy remains a mainstay for triple-negative breast cancer (TNBC). The epithelial-to-mesenchymal transition (EMT) is a developmental program co-opted by cancer cells that promotes metastasis and chemoresistance. There are no therapeutic strategies specifically targeting mesenchymal-like cancer cells. We report that the US Food and Drug Administration (FDA)-approved chemotherapeutic eribulin induces ZEB1-SWI/SNF-directed chromatin remodeling to reverse EMT that curtails the metastatic propensity of TNBC preclinical models. Eribulin induces mesenchymal-to-epithelial transition (MET) in primary TNBC in patients, but conventional chemotherapy does not. In the treatment-naïve setting, but not after acquired resistance to other agents, eribulin sensitizes TNBC cells to subsequent treatment with other chemotherapeutics. These findings provide an epigenetic mechanism of action of eribulin, supporting its use early in the disease process for MET induction to prevent metastatic progression and chemoresistance. These findings warrant prospective clinical evaluation of the chemosensitizing effects of eribulin in the treatment-naïve setting.

INTRODUCTION

The epithelial-to-mesenchymal transition (EMT) is a cellular program that imparts plasticity to epithelial cells, enabling them to acquire traits such as motility and invasion.¹ EMT is an integral step in developmental processes such as gastrulation and neural crest migration and normal processes such as wound healing. Cancer cells frequently co-opt EMT, and its roles in tumor progression are well studied, including in triple-negative breast cancers (TNBCs) that lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. In addition to contributing to the local invasion of primary tumor cells and enabling intravasation into blood/lymphatic vessels, EMT plays roles in tumor cell extravasation and chemoresistance.^{1,2} Despite our understanding of EMT and the signaling pathways and transcriptional networks that regulate this plasticity in diverse cellular contexts, the impact of EMT research

on therapeutic targeting of cancers has been minimal. While there are US Food and Drug Administration (FDA)-approved therapies that may modulate EMT, there are no approved drugs administered specifically for their ability to modulate EMT. Indeed, there is a gap between (1) our biological understanding of EMT and (2) translation of that knowledge to improve clinical outcomes.

Eribulin (ERI) is a microtubule dynamics inhibitor administered to patients with advanced/metastatic breast cancer in the third-line setting or later.³ These patients have often received prior chemotherapy that included an anthracycline and a taxane. The proposed primary mechanism of ERI action is inhibition of tubulin addition to the plus end of microtubules, thereby inducing mitotic blockade.⁴ Through a seemingly unconnected molecular mechanism, ERI has been shown to induce mesenchymal-to-epithelial transition (MET) in some models^{5–7} and also in combination therapy,⁸ but the underlying molecular mechanism and



therapeutic consequences remain unclear. We thus undertook studies using TNBC cell lines, murine and patient-derived xenograft (PDX) models, and patient-matched primary human tumor specimens acquired before and after neoadjuvant therapy to illuminate the MET-inducing mechanism of ERI action and identify therapeutic strategies to capitalize upon this mechanism.

RESULTS

Therapeutic induction of MET in breast cancer cells

Given the previously demonstrated role of eribulin in the modulation of the EMT state,⁵ we sought to compare its effects with those of other chemotherapeutics within the same class of microtubule dynamics inhibitors. Paclitaxel (PAC) is used in neoadjuvant chemotherapy for breast cancer, and vinorelbine (VIN) and ERI are administered to treat advanced breast cancers. All 3 drugs inhibited the growth of PB3 cancer cells derived from a mouse mammary tumor virus promoter-driven polyoma virus middle T antigen (*MMTV-PyMT*) transgenic murine triple-negative mammary tumor (Figure 1A), which resides in a quasi-mesenchymal state.⁹ To mimic clinical treatment regimens in the development of drug-resistant cell lines, chemotherapeutics were applied intermittently to PB3 cells for 3 cycles, allowing for intervening drug holidays for cells to recover (Figure 1B). Treatment with eribulin at its half-maximal inhibitory concentration (IC_{50}), but not with vinorelbine or paclitaxel at their IC_{50} , led to the emergence of a drug-resistant cell population (PB3^{ERI-R}) exhibiting upregulated levels of epithelial cell markers (i.e., epithelial cell adhesion marker [EpCAM] and E-cadherin), downregulated levels of mesenchymal markers (vimentin and Zeb1), and an epithelial cobblestone-like morphology compared with PB3 controls, vinorelbine-resistant derivatives (PB3^{VIN-R}), and paclitaxel-resistant derivatives (PB3^{PAC-R}) (Figures 1C and S1A–S1C). The altered phenotype of ERI-R cells was accompanied by decreased migration and invasion potential compared with PB3 controls (Figures 1D, 1E, and S1D). Chemotherapeutics were removed from drug-resistant cells 4 weeks prior to seeding for assays, indicating that these phenotypes were stable and not due to the continued presence of drugs. Similar effects of eribulin treatment were observed in human TNBC cells; ERI-R derivatives of MDA-MB-231 and SUM159PT cells showed increased E-cadherin and decreased VIM and ZEB1 (Figures 1F, 1G, and S1E–S1I).

Orthotopic implantation of parental PB3 cells or isogenic PB3^{VIN-R} or PB3^{PAC-R} cells into female non-obese diabetic (NOD)/severe combined immunodeficiency (SCID)/*IL2R γ ^{-/-}* (NSG) mice resulted in robust tumor growth. However, PB3^{ERI-R} cells did not readily form tumors and exhibited a more than 100,000-fold reduction in tumor initiation ability (Figures 1H and I). Furthermore, PB3^{ERI-R} cells did not form spontaneous lung metastases despite the other cell lines yielding abundant lung lesions established from mammary fat pad implantation (Figures 1J and 1K), which may have resulted from differences in primary tumor sizes; however, PB3^{ERI-R} cells were not able to initiate tumors. Cells that show CD44^{hi}/CD104⁺ markers (such as MDA-MB-231, MDA-MB-231^{VIN-R}, and MDA-MB-231^{PAC-R}) are known to have a greater ability to initiate tumors compared with cells with CD44^{lo}/CD104⁺ markers (like MDA-

MB-231^{ERI-R}). These cell groups can be classed as purely epithelial cells (CD44^{lo}/CD104⁺, like MDA-MB-231^{ERI-R}), quasi-mesenchymal to mesenchymal cells (CD44^{hi}/CD104⁺, like MDA-MB-231^{VIN-R} and MDA-MB-231^{PAC-R}), and highly mesenchymal cells (CD44^{hi}/CD104⁻).¹⁰ MDA-MB-231^{ERI-R} cells also displayed a decrease in the cancer stem cell marker CD44 (Figure S1J), aligning with the reduced observed ability to start tumors in PB3^{ERI-R} cells (Figures 1H and I). These results confirm the ability of eribulin to induce MET in breast cancer cells, driving cells toward an epithelial state accompanied by a significant reduction in tumor initiation potential.

Eribulin drives MET in human TNBC

We evaluated TNBC diagnostic core biopsy (pre-treatment) and surgical (post-treatment) specimens from patients treated with neoadjuvant chemotherapy. SOLTI1007 NeoEribulin specimens were obtained from 55 patients who received 4 cycles of neoadjuvant eribulin.¹¹ Comparator specimens were from 15 patients who received standard-of-care neoadjuvant treatment with 4 cycles of adriamycin/cyclophosphamide followed by 4 cycles of paclitaxel (AC-T).

Specimens were multiplex immunostained for 6 EMT markers.¹² To enumerate ratios of epithelial and mesenchymal cell types, cells were grouped based on marker expression (Figures 2A and B). In addition, we identified two new phenotypes (KRT8⁺, and ZEB1⁺/VIM⁺) that offer a more comprehensive representation of marker expression patterns. AC-T-treated tumors did not undergo major shifts in subtype proportions. In contrast, eribulin-treated tumors exhibited ~20% and ~30% increases in expression of E-cadherin [E-cad]⁺/KRT8⁺ and KRT8⁺ epithelial phenotypes, respectively, commensurate with decreases of ~50% in VIM⁺ and ZEB1⁺/VIM⁺ mesenchymal phenotypes (Figure 2B).

EMT scores were generated for each tumor specimen, with “0” being most epithelial and “1” being most mesenchymal. Tumors treated with neoadjuvant eribulin showed a 41.7% mean decrease in EMT score compared with baseline ($p < 0.0001$), reflecting a shift toward an epithelial phenotype. In contrast, neoadjuvant AC-T did not significantly alter the EMT score (Figure 2C).

Clonal dynamics reveal induction of the epithelial-like phenotype in chemotherapy-resistant cells

Drug treatment of a heterogeneous cell population results in a diverse array of fates that are determined in part by the starting transcriptional and epigenetic states of each cell. To elucidate the cellular trajectories that result from drug treatment, we developed an approach to query indexed sequences and simultaneously measure epigenetic timelines (QISSMET). Similar approaches have been utilized to trace cell lineage through therapeutic bottlenecks.^{13,14} By analyzing changes in transcriptional and chromatin accessibility profiles induced by drug selection, QISSMET enables differentiation between pre-existing drug-resistant cells and emerging *de novo* cell types with acquired resistance. Changes that a given cell undergoes upon drug treatment would manifest as changes in gene expression and chromatin state, which would imply epigenetic reprogramming leading to the emergence of a *de novo* cell state.




Figure 1. Eribulin induces MET in TNBC cells

(A) Dose-response curves in PB3 cells were generated to calculate IC₅₀ values for eribulin, paclitaxel, and vinorelbine. (B) Schematic of the multiround drug treatment procedure that resulted in the generation of drug-resistant cells. (C–G) Estimation of EMT state was carried out by immunoblotting (C, F, and G), Transwell invasion assay 8 h post-seeding (D), and wound closure assay 16 h post seeding (E). Data are shown as mean of biological triplicates ± SD. (H–K) PB3 parental and drug-resistant cells were implanted orthotopically. In (H), tumor volumes were serially measured. Tumor-initiating capacity (TIC) was assessed by limiting dilution transplantation (I). In (J), metastatic ability was assessed in lungs harvested from mice in (H) and stained with H&E. Metastases were enumerated in (K). Data in (H and K) are shown as mean of 10 mice ± SD. **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001; ns, not significant by Tukey-adjusted pairwise comparison.

Alternatively, if no changes in gene expression or chromatin state are observed, this would suggest that a selection event had occurred, amplifying a pre-existing drug-resistant population.

To characterize the nature of drug-resistant cells, we stably transfected PB3 cells with an expressed barcode library. Barcoded cells were subject to 3–4 cycles of treatment with eribulin or paclitaxel (Figure 3A), and an aliquot of cells was harvested before each cycle for single-cell RNA sequencing

(scRNA-seq). Eribulin treatment resulted in the emergence of cells (ERI3 and ERI4) that clustered distinctly from the untreated parental population by transcriptomic analysis, while paclitaxel did not (Figure 3B). Monocle pseudotime kinetics^{15–17} revealed that cells undergoing eribulin treatment took multiple trajectories from the most primitive (parental) to the most advanced (ERI4) transcriptional state (Figure 3C). In contrast, cells undergoing paclitaxel treatment took fewer




Figure 2. Eribulin promotes MET in human TNBC

Multiplexed, multiround TSA staining of EMT markers was performed in TNBC specimens acquired from patients before and after neoadjuvant treatment with eribulin or AC-T.

(A) Representative images.

(B) Proportions of tumor cells expressing markers of EMT phenotypes.

(C) EMT scores of tumors. **** $p < 0.0001$; ns, not significant by Tukey-adjusted pairwise comparison.

distinct paths and remained more akin to parental controls without uniform directionality (Figure 3D).

We sought to determine whether eribulin treatment led to (1) an induction event that generated resistant cells with altered chromatin and transcriptional profiles or (2) the selection of pre-existing drug-resistant cells that were epigenetically/transcriptionally similar to the parental population. We selected the 28 most highly enriched barcodes that contained 1 or more cells in both the control and drug-treated clusters, and we calculated their Euclidean distances based on median positions on uniform manifold approximation and projection (UMAP) plots. Drug-resistant cells with barcodes that had larger Euclidean distances resided in the far left (“induction” region) of the UMAP, while drug-resistant cells with barcodes that had smaller Euclidean distances resided in the bottom island (“selection” region) of the UMAP (Figures 3E and 3F). Cells treated with eribulin had significantly larger Euclidean distances than cells treated with paclitaxel (median, 11.74 vs. 5.59; Figure 3G). Using a combination of Euclidean distance and Jaccard index, we calculated that 92% of barcodes in eribulin-resistant cells localized to the induction region, indicating that they underwent a shift in transcriptional profile as a result of eribulin treatment. In contrast, paclitaxel-resistant cells were transcriptionally more similar to the parental population, with 50% of barcodes localizing to the selection region (Figures 3H and S2A–S2E).

In addition to exhibiting altered transcriptional profiles, the epithelial-like cell subpopulations that emerged from eribulin treatment also exhibited altered chromatin landscapes, as observed by single-cell assay for transposase-accessible chro-

matin using sequencing (scATAC-seq; Figures S2F and S2G). Plotting the evolutionary trajectories of cells as they underwent drug treatments revealed that both agents imposed severe bottlenecks that only a few barcodes (i.e., individual cells) overcame. While eribulin treatment resulted in the emergence of a dominant clonal subpopulation, clonal frequencies were preserved with less variation upon paclitaxel treatment (Figures 3I and 3J). These results indicate that, in comparison with paclitaxel, eribulin treatment led to the evolution of resistant cells that were distinct from parental cells, consistent with their having undergone MET (Figure 1) and reprogramming of transcriptional and chromatin states.

Treatment with eribulin induces a shift in the chromatin profiles of cancer cells

In light of the observed functional properties of eribulin, we sought to further explore its mechanism of action that contributes to its ability to induce MET and therapeutic consequences. PB3^{ERI-R} cells exhibited a significantly altered bulk transcriptional profile relative to parental PB3, PB3^{PAC-R}, and PB3^{VIN-R} cells (Figures 4A, 4B, and S3A). Gene set enrichment analysis revealed significant enrichment for hallmark gene sets involved in EMT, the majority of which were downregulated in PB3^{ERI-R} cells compared with parental controls (Figures 4C and D).

We reasoned that transcriptomic changes may result from alterations in chromatin state. Indeed, the levels of the histone 3 lysine 4 trimethylation (H3K4me3) activation mark and the H3K27me3 repressive mark were both reduced in ERI-R derivatives, but not PAC-R or VIN-R derivatives, from PB3, MDA-MB-231, and SUM159 TNBC cells (Figures 4E, and S3B). H3K4me3




Figure 3. Clonal dynamics following drug treatment

(A) Schematic outlining genetic barcoding of cells and subsequent drug treatment strategy.

(B) UMAP projection of scRNA-seq data obtained from PB3 cells before and after 1–4 rounds of treatment with eribulin or paclitaxel.

(C and D) Monocle pseudotime projection showing the trajectory of cancer cell evolution upon drug treatment. The main lineage path or master path/node is indicated by “1” in a white circle. Sublineages (leaf nodes) from the master path are indicated by numbers in gray circles. Branches from leaf nodes are indicated by numbers in black circles. Left and right: cells colored according to pseudotime and sample, respectively.

(legend continued on next page)

cistrome profiling revealed overall reduced representation of this activating histone mark in PB3^{ERI-R} cells (Figure 4F). However, this reduction in H3K4me3-DNA binding was not universal, with some genomic loci coding for epithelial markers such as *Cdh1*, *Grhl1*, *Ovol1*, and *Ovol2* gaining this mark in promoter regions in PB3^{ERI-R} cells but not PB3^{PAC-R} or PB3^{VIN-R} cells (Figure 4G).

Assessing the chromatin accessibility landscape of cells by bulk ATAC-seq also revealed a more closed chromatin profile with fewer and different accessible regions of chromatin in PB3^{ERI-R} cells compared with parental controls (Figures 4H, S3C and S3D). Consistent with H3K4me3 profiling, chromatin surrounding loci encoding epithelial markers (*Cdh1*, *Ovol1*, and *Ovol2*) was more accessible in PB3^{ERI-R} cells (Figure 4I). Integrated analysis of bulk RNA-seq and ATAC-seq data with DiffTF¹⁸ inferred large-scale changes in the activity of key transcription factors in PB3^{ERI-R} cells compared with parental controls but not in PB3^{VIN-R} or PB3^{PAC-R} cells (Figures 4J, S3E, and S3F). These data collectively point to eribulin treatment resulting in more pronounced reprogramming of the chromatin and transcriptional states of TNBC cells compared with other microtubule dynamics inhibitors, suggesting alternate mechanisms of drug action.

ZEB1-SWI/SNF interactions are required for maintenance of the mesenchymal state

To identify protein targets involved in chromatin/transcriptional responses to eribulin, we conducted an unbiased proteome integral solubility alteration (PISA) assay¹⁹ to identify proteins that exhibit altered thermal stability within 4 h in the presence of eribulin in PB3 cells. Among 6,527 proteins detected in all samples, 40 proteins had significant ($p < 0.05$) alterations in thermal stability ($\Delta S_m \geq 0.5$) due to eribulin treatment (Tables S1 and S2). We focused validation studies on proteins with known roles in chromatin regulation. Smrd1 (*Smarcd1*) and Smrd3 (*Smarcd3*) are switch/sucrose non-fermentable (SWI/SNF)-family ATP-dependent chromatin remodelers that exhibited thermal stability shifts upon eribulin treatment, indicating that they may be bound by the drug (Figures 5A and S4A). CRISPR-Cas9-mediated knockout of *Smarcd1*, *Smarcd2*, or *Smarcd3* (individually and all three together) in PB3 cells reduced the spindle-shaped (mesenchymal-like) morphology, reduced Zeb1 levels, and increased E-cad (Figures 5B, S4B, and S4C). Triple knockout of *Smarcd1/2/3* phenocopied eribulin treatment, shifting PB3 and MDA-MB-231 cells toward an epithelial state (Figures 5B, S4D, and S4E) and phenocopied eribulin-induced decreases in H3K4me3 and H3K27me3 (Figure 5C). Rescue through the expression of exogenous human *SMARCD1* in *Smarcd1* knockout PB3 cells suppressed E-cad levels and restored Zeb1, indicating that SMARCD1/Smrd1 signaling drives a mesenchymal state (Figure S4F).

Previous work has shown that members of the SWI/SNF family can interact with the transcription factor ZEB1, enabling

repression of E-cad (*CDH1*) transcription and inducing EMT.²⁰ We hypothesized that the specificity of SMARCs proteins for EMT traits could be a result of interaction with ZEB1 to modulate ZEB1 function. Indeed, we observed Zeb1/ZEB1 interactions with Smarcd1/SMARCD1, Smarcd3/SMARCD3, and Smarcc1/SMARCC1 in PB3 and MDA-MB-231 cells (Figures 5D, S4G, and S4H). These interactions were altered by treatment with eribulin.

We tested the effects of interactions between Zeb1/Smard1 and Zeb1/Smarcc1 on DNA binding and transcriptional activity. In PB3 and MDA-MB-231 cells, eribulin progressively reduced Zeb1/ZEB1 binding to DNA across the genome (Figure 5E, 5F, S4I, and S4J). Eribulin elicited a time-dependent reduction in Zeb1 binding to the promoter regions of the epithelial target genes *Cdh1* and *Mmp2* and to other targets (*Sox9*, *Vegfa*, and *Jun*)^{21,22} (Figures 5G and S4K). These results point to roles of Smard1 and Smarcc1 as essential Zeb1 co-factors for the maintenance of a mesenchymal state.

Order of exposure to chemotherapeutics alters efficacy

Current treatment strategies for stage I-III TNBC often include the administration of neoadjuvant chemotherapy (NAC) consisting of several cycles of an anthracycline (e.g., adriamycin) with cyclophosphamide, followed by several cycles of a taxane (e.g., paclitaxel) prior to surgical resection of the tumor. Patients with advanced/metastatic TNBC are treated with agents such as vinorelbine or eribulin, where eribulin is approved for use following treatment with 3 or more lines of chemotherapy and prior exposure to an anthracycline and a taxane. We found that primary treatment of TNBC cells with eribulin resulted in the generation of epithelial-like ERI-R cells (Figures 1C–1F). It is generally accepted that epithelial-like cancer cells are more chemosensitive than mesenchymal-like cancer cells.^{1,2} We therefore sought to determine the MET-inducing effects of eribulin on sensitization to other chemotherapeutics. Treatment of PB3^{ERI-R} cells with either paclitaxel or vinorelbine drastically increased senescence (50%–60%) and apoptosis (35%–50%) (Figures 6A, 6B, S5A, and S5B). Conversely, eribulin treatment of PB3^{PAC-R} or PB3^{VIN-R} cells induced modest senescence (<10%) and apoptosis (~10%) (Figures 6C, S5C, and S5D). Similar effects were observed in growth assays with PB3 and MDA-MB-231 derivative cells. PB3 and PB3^{ERI-R} cells showed respective vinorelbine IC₅₀ values of 279.32 nM and 76 nM and respective paclitaxel IC₅₀ values of 303.34 nM and 112.46 nM (Figure 6D), reflecting an ~3-fold increase in chemosensitivity in ERI-R cells. Conversely, PB3^{PAC-R} and PB3^{VIN-R} cells showed relative resistance to eribulin (Figures 6E and 6F). In parallel, MDA-MB-231^{ERI-R} cells showed increased sensitivity to paclitaxel and vinorelbine compared with parental MDA-MB-231 cells, while MDA-MB-231^{PAC-R} and MDA-MB-231^{VIN-R} cells showed relative resistance to eribulin (Figures 6G–6I). MDA-MB-231^{ERI-R} cells also exhibited ~70% senescence upon treatment with vinorelbine or paclitaxel, whereas MDA-MB-231^{PAC-R}

(E–G) Euclidean distance between ERI4 vs. untreated cells (E) or PAC3 vs. untreated cells (F), with the same barcode are shown in swimmer plots, and UMAPs represent median points of ERI4 or PAC3 and untreated cells. **** $p < 0.0001$ by Mann-Whitney U test.

(H) Proportions of induction vs. selection resistance for ERI and PAC treatments were compared by chi-square test.

(I and J) Muller plots outlining clonal diversity of the 10 most abundant barcodes following drug treatment.

and MDA-MB-231^{VIN-R} cells showed 3%–6% senescence in response to reciprocal drugs (Figure S5E). These results suggest that pharmacological MET induction with an agent such as eribulin efficiently sensitizes therapy-naïve TNBC cells to other microtubule-targeted chemotherapeutics.

Pharmacological MET induction is associated with chemosensitization *in vivo*

To determine how MET induction via eribulin treatment affects tumor growth and metastatic progression, we first randomized mouse mammary tumor virus promoter-driven polyomavirus middle T antigen-expressing (MMTV-PyMT) transgenic female mice bearing late-stage triple-negative mammary tumors²³ to drug treatments. While vinorelbine and paclitaxel each stunted tumor growth, eribulin led to robust tumor regression in all cases (Figure 7A). Furthermore, eribulin induced a near-complete inhibition of metastatic growth in the lungs that was significantly more effective than other drugs (Figure 7B). In contrast to vinorelbine or paclitaxel, which resulted in high-grade, poorly differentiated tumors containing an abundance of vimentin-expressing (i.e., mesenchymal-like) tumor cells, eribulin resulted in low-to moderate-grade, well-differentiated tumors containing islands of malignant cells primarily expressing the epithelial marker E-cad (Figures 7C, and S6A).

To determine the effects of prior chemotherapy exposure on sensitization to additional chemotherapeutics, tumor-bearing MMTV-PyMT mice received primary treatment with 5 doses of (1) paclitaxel or (2) vinorelbine over 2 weeks. Palpable tumors were surgically resected. After a 2-week drug holiday, mice received secondary treatment with eribulin for 2 weeks. Conversely, groups of mice that received primary treatment with eribulin for 2 weeks followed by resection and a 2-week drug holiday then received secondary treatment with (3) paclitaxel or (4) vinorelbine for 2 weeks. Tumors that emerged following primary eribulin treatment underwent robust regression in response to secondary paclitaxel or vinorelbine (Figure 7D). In contrast, secondary eribulin only induced stasis in tumors in mice that received primary vinorelbine or paclitaxel. Moreover, tumors harvested following primary eribulin plus secondary paclitaxel/vinorelbine (and a subsequent 1-week holiday) contained lower proportions of vimentin-expressing (mesenchymal-like) malignant cells and higher proportions of E-cad-expressing (epithelial-like) malignant cells compared with tumors exposed to secondary eribulin (Figure 7E). These

observed differences in primary tumor growth and composition were reflected in differences in lung metastases; primary eribulin provided near-complete abrogation of metastatic propensity in lungs analyzed after secondary treatments (Figure 7F).

Chemotherapy exposure in patients directs drug sensitivity in xenografts

Our observations in cultured cells and MMTV-PyMT transgenic mice suggest that the order of exposure to chemotherapeutics dictates outcome; primary eribulin treatment may induce MET and sensitize TNBC cells to other chemotherapeutics, but primary treatment with other chemotherapeutics did not sensitize cells to eribulin. Such findings have clinical implications because patients with TNBC are commonly treated with an anthracycline, cyclophosphamide, and a taxane in the (neo)adjuvant setting long before the third-line treatment or more of recurrent/metastatic disease with eribulin. We thus tested drug effects in orthotopic PDX models established from primary TNBC tumors from patients who did or did not receive prior NAC. JAX-98^{naïve} and NCI-140^{naïve} PDX models were derived from treatment-naïve patients. While 2 weeks of treatment with paclitaxel and vinorelbine inhibited the growth of JAX-98^{naïve} and NCI-140^{naïve} tumors, eribulin induced near-complete regression (Figures 7G and S6B). Tumors harvested after a 1-week drug holiday showed that eribulin induced differentiation with an abundance of E-cad-expressing cells (Figures 7H and S6C–S6E). In tumors that regrew following primary eribulin treatment, secondary vinorelbine and paclitaxel each provided robust regression (Figures 7I and S6F). Following secondary drug treatment, the remaining PDX tumors were resected, and mice were maintained for 3 months prior to organ harvest to assess metastasis. JAX-98^{naïve} engrafted mice showed metastases to lungs, liver, ovaries, and axillary lymph nodes. Primary eribulin followed by secondary paclitaxel or vinorelbine reduced metastatic occurrence, while the reverse order of treatments was less protective (Figures 7J and 6G).

The NCCC-470^{NAC} and JAX-91^{NAC} PDX models were derived from patients pre-treated with NAC. NCCC-470^{NAC} tumors were resistant to all 3 chemotherapy drugs administered alone or in sequence (Figures 7K and 7L), tumors retained poor differentiation status without changes in the proportion of vimentin-expressing cells, and metastases (3 months post secondary drug treatment) were only marginally affected by primary eribulin treatment in sequence with paclitaxel/vinorelbine (Figures 7M,

Figure 4. Eribulin induces a shift in transcriptional and chromatin profiles of TNBC cells

(A–D) PB3 parental and drug-resistant cells were analyzed by bulk RNA-seq in biological duplicates. In (A), a heatmap shows the top 500 most differentially expressed genes. Genes significantly altered in drug-resistant cells vs. parental controls (\log_2 -fold-change indicates mean expression level; Benjamini-Hochberg-corrected p value threshold = 0.01) are highlighted in volcano plots in (B). A dot plot outlining enrichment of hallmark gene sets in ERI-R vs. control cells is shown in (C); circle size depicts pathway significance, and red and blue dots indicate activated and suppressed pathways, respectively. Shown in (D) is a heatmap of EMT and chromatin organization genes in hallmark gene sets.

(E) Immunoblot of lysates from PB3 and MDA-MB-231 parental and drug-resistant cells.

(F) Top: average CUT&RUN enrichment profile of H3K4me3 in PB3 control and drug-resistant cells. Bottom: heatmap of CUT&RUN signal ± 4 kb of peaks.

(G) H3K4me3 localization at genomic loci of canonical EMT genes as evaluated by CUT&RUN signal track analysis.

(H and I) Bulk ATAC-seq was performed in PB3 parental and drug-resistant cells. Peak accessibility surrounding all consensus regions (H, top), promoter-associated regions (H, bottom), and EMT marker genes (I) is shown.

(J) ATAC-seq and RNA-seq integration analysis. Shown are advanced volcano plots of highly significant transcription factors (TFs) as determined by DiffTF from ATAC-seq (x axis) and \log_2 fold change in gene expression of TFs (y axis). TF classification is indicated by circle color. The number of TF binding sites used to determine TF activity is indicated by circle size.




Figure 5. ZEB1-SWI/SNF interactions are necessary for maintenance of a mesenchymal state

(A) PB3 cells treated with or without 300 nM eribulin for 4 h were analyzed by PISA assay. Proteins were plotted by Δ Sm and $-\log_{10}p$ (t test). (B and C) Immunoblot analysis of cells with CRISPR-Cas9-mediated deletion of Smarcd1 (D1), Smarcd3 (D3), or Smarcd1/2/3. (D) Zeb1 and Smarcc1 immunoprecipitates and lysates from cells treated with or without eribulin for 48 h. (E–G) Genomewide occupancy of Zeb1 in PB3 cells treated with or without eribulin for 24, 48, or 72 h was evaluated using CUT&RUN. In (E), average CUT&RUN enrichment profiles (top) and heatmap of the CUT&RUN signal ± 2 kb of peaks (bottom) are shown. Shown in (F) are UpSet plots of differentially accessible peaks at the indicated time points as mean \pm SEM. Signal tracks of Zeb1 localization at target gene loci are shown in (G).

7N, and S4H). While JAX-91^{NAC} tumors behaved similarly to those of the treatment-naïve models in response to single-agent drug treatment (Figure S6I–S6K), tumors that regrew following primary eribulin treatment were insensitive to secondary paclitaxel/vinorelbine (Figure S6L and S6M).

Metastasis and EMT are early events in the tumorigenic process, and patients presenting with early-stage breast cancer often already have disseminated cancer cells in other organs.^{24,25} It is thus imperative in preclinical studies to assess therapeutic effects on metastases. We injected luciferase-expressing MDA-MB-231 cells via the tail vein to establish lung metastases. Two weeks later, metastases were detected by bioluminescence imaging, and mice were treated with 4 rounds of vehicle, paclitaxel, vinorelbine, or eribulin. While vinorelbine and paclitaxel slowed (or did not affect) the growth of lung metastases, eribulin induced near-complete regression (Figures 7O–Q).

Eribulin reduces epithelial-mesenchymal heterogeneity in tumors

Primary eribulin treatment increased proportions of E-cad-expressing cells and decreased vimentin-expressing cells in TNBC PDX models (Figures 7H, 7M, S6E, and S6K). EMT scoring of PDX specimens showed that eribulin induced significant epithelial shifts in EMT score in NCI-140^{naïve}, JAX-98^{naïve}, or JAX-91^{NAC} tumors. In contrast, NCCC-470^{NAC} tumors did not exhibit a shift in EMT score upon eribulin treatment (Figures

S7A–S7F), in line with resistance to eribulin-induced MET (Figure 7M). Paclitaxel did not significantly alter EMT score in any tumor model. Primary eribulin followed by secondary paclitaxel (E1P2) provided significantly lower EMT scores than the converse (P1E2) in NCI-140^{naïve}, JAX-98^{naïve}, and JAX-91^{NAC} tumors (Figures S7A–S7F), affirming the contribution of drug order to EMT phenotype.

We also quantified tumor response to therapy based on changes in proportions of cancer vs. stromal cells. Eribulin significantly reduced proportions of cancer cells in all PDX models; such effects were most consistently observed in NCI-140^{naïve} and JAX-98^{naïve} tumors, while NCCC-470^{NAC} and JAX-91^{NAC} tumors showed more heterogeneity (Figures S7G–S7J). In contrast, paclitaxel had no significant effect on proportions of cancer cells within tumors. E1P2 caused significant decreases in cancer cell proportions in NCI-140^{naïve} and JAX-98^{naïve} tumors compared with P1E2—effects not observed in NCCC-470^{NAC} and JAX-91^{NAC} tumors. These data reinforce our observations that the effects of eribulin on MET induction and tumor regression are most profound when administered in the treatment-naïve setting.

DISCUSSION

Using a combination of TNBC cells, genetically engineered mouse models, and PDX, we uncovered a mechanism through




Figure 6. Eribulin pre-treatment induces sensitization to subsequent chemotherapy

(A–C) Senescence-associated β -galactosidase assay and quantification of apoptotic cells. PB3 parental and drug-resistant cells were used as indicated and treated with paclitaxel (A), vinorelbine (B), or eribulin (C). Data are shown as mean of duplicates \pm SEM.

(D–F) PB3 parental and drug-resistant cells were used to generate dose-response curves to determine IC₅₀. (G–I) MDA-MB-231 parental and drug-resistant cells were treated as in (D)–(F). Data are shown as mean of triplicates \pm SEM.

which ZEB1 interacts with members of the SWI/SNF family of chromatin remodelers to maintain the mesenchymal state. This interaction, when disrupted using pharmacologically achievable concentrations of eribulin, induces MET and alters the differentiation state of tumor cells. This MET is accompanied by reduced tumor initiation capacity, reduced metastatic propensity, and increased chemosensitivity. Through a combination of lentiviral barcoding and single-cell analyses, we found that disrupting the ZEB1-SWI/SNF interaction using eribulin reprograms the chromatin and transcriptional profiles of TNBC cells, shifting their evolutionary trajectory as they progress through the bottlenecks of treatment. This work advances the understanding of how cancer cells utilize optimal chromatin remodeling machinery to maintain a mesenchymal state that imparts aggressive traits while unveiling a mechanism of action for eribulin to modulate cancer cell state, paving the way for optimal clinical use to exploit its multifaceted anti-tumor properties.

Therapeutic targeting of EMT has long been pursued as an attractive means of sensitizing tumors that exhibit mesenchymal-like traits to conventional chemotherapy.^{2,26–28} The prevailing understanding of the role of EMT in the invasion-metastasis cascade posits that cancer cells that acquire invasive traits by undergoing EMT often endure a reversal of this program via MET at a distant metastatic site, thereby enabling the colonization of foreign tissues by imparting proliferative traits.^{29,30} Such a notion would argue against the induction of MET as a

possible therapeutic avenue, given the possibility of inadvertently promoting the colonization of cancer cells that have already embarked on the metastatic cascade and disseminated to distant sites. However, our data demonstrating the ability of eribulin to induce regression of established metastases provide evidence that MET induction could prove beneficial in countering metastatic progression. The regression of metastases induced by eribulin may be a result of its MET-inducing properties and/or anti-mitotic effects. The inability of paclitaxel or vinorelbine to eradicate metastases indicates that anti-mitotic effects alone are insufficient to achieve regression of established metastases.

A remaining question is whether cancer cells of both intermediate/hybrid and extreme mesenchymal-like states are equally susceptible to eribulin-induced MET. The PB3 and MDA-MB-231 TNBC cells used in our study reside in hybrid/quasi-mesenchymal states that can be reversed toward epithelial-like states through pharmacological or genetic means.^{9,31–34} In contrast, mesenchymal-like SUM159 cells showed more modest MET in response to eribulin (Figures 1C–1G and S1C–S1G), possibly due to their residence in a state that is less permissive to reversion. We previously observed a similar refractory response to MET induction by activation of PKA signaling in some cell systems,²⁸ pointing to a more generalizable inability of cells that have advanced beyond a certain point along the epithelial-mesenchymal (E-M) spectrum to regain epithelial traits. Ample evidence points to the aggressive nature of cells residing in an intermediate EMT state that exhibit




Figure 7. MET induction is accompanied by robust tumor regression and reduced metastatic burden

(A–C) MMTV-PyMT tumor-bearing female mice were treated with vehicle, paclitaxel (20 mg/kg), vinorelbine (7 mg/kg), or eribulin (1.6 mg/kg) twice weekly to assess (A) tumor growth rate, (B) tumor metastasis to the lungs (red arrows), and (C) EMT status using immunofluorescence of E-cad (green) and vimentin (red). Tumors and lungs were harvested after 2 weeks of drug treatment and a 1-week drug holiday. (D–F) MMTV-PyMT mice were treated as in (A), and palpable mammary tumors were surgically resected. After a 2-week drug holiday, mice were treated with a second round of therapy to assess tumor growth rate (D), EMT status (E), and tumor metastasis to lungs (F). Tumors and lungs were harvested after a 1-week drug holiday.

(legend continued on next page)

enhanced metastatic ability.^{12,31,33,35,36} Whether targeting of extreme mesenchymal cell states holds therapeutic value is unknown, but recent work suggests that mesenchymal-like cancer cells may retain plasticity to acquire epithelial traits following treatment with chemotherapy.³⁶

Drug treatment of cell populations typically results in a mixture of cell fate outcomes that are influenced in part by chromatin state. Using a combination of cellular barcoding and gene expression analyses (QISSMET), we developed a method to study the mode of resistance that drives drug resistance of populations, specifically grouping cells into two categories per prior definitions:³⁷ Darwinian selection for cells where the terminal treatment UMAP state is similar to untreated cells and Lamarckian induction for cells where the terminal treatment UMAP state is transcriptionally distinct from that of untreated cells. QISSMET enables the uncovering of cellular trajectories as cells overcome treatment, and it became evident that the same drug can invoke different outcomes in a population of cells, likely determined by baseline chromatin and EMT states. The Muller plot in Figure 2I shows that eribulin treatment imposes a bottleneck that only a subpopulation of cells can overcome by undergoing a shift in their transcriptional and chromatin landscapes, reminiscent of previously described cancer stem cell subpopulations that drive relapse following therapy.^{26,38,39}

We uncovered a mechanism that serves to maintain a mesenchymal state in TNBC cells by altering the transcriptional functionality of the key EMT factor ZEB1 through its interaction with the SMARCC and SMARCD members of the SWI/SNF chromatin remodeling complex. Several chromatin modulators have been implicated in the regulation of ZEB1, including CtBP, LSD1, HDAC1/2, and BRG1.^{20,40–42} Several of these interactions could constitute attractive therapeutic targets in EMT, such as work demonstrating that the histone deacetylase (HDAC) inhibitor mocetinostat reverses ZEB1-associated drug resistance.⁴³ While HDAC inhibitors are FDA approved for certain indications and serve as proof-of-principle epigenetic therapeutics, the lack of a specific protein target has proven to be a hurdle in their success as widely used anti-neoplastic agents. We showed that eribulin, a microtubule dynamics inhibitor, alters the chromatin landscape of TNBC cells by interfering with interactions between ZEB1 and SWI/SNF complex members, providing a potential secondary mechanism of anti-cancer action.

Our findings have significant implications for the development of more effective treatment regimens for breast cancer patients. Analysis of tumors from the SOLTI1007 study revealed that treatment of patients with eribulin in the neoadjuvant setting can induce a reversion of tumor cells to a more epithelial-like state. We also observed in preclinical models that the chromatin-modulating and cellular reprogramming effects of eribulin enable pre-treatment with this agent to sensitize TNBC cells to other

chemotherapeutics. Thus, there may be therapeutic value in using eribulin pre-treatment as an MET-inducing step, specifically for patients with tumors that exhibit EMT features. There are currently no clinical means to stratify patients by the extent of tumor EMT as a biomarker that could inform therapeutic decision-making, with the closest surrogate being a histopathological estimate of differentiation state. Our recently developed multiplexed immunostaining approach to quantify the extent of tumor epithelial-mesenchymal heterogeneity¹² may enable the identification of patients that may benefit from pre-treatment with MET-inducing regimens with drugs such as eribulin prior to receiving standard NAC. In summary, we unveiled how a more refined understanding of the mechanism of action of an FDA-approved drug, including its effects on epithelial-mesenchymal plasticity, can open avenues to potentially improve clinical outcomes. Prospective clinical testing is warranted to evaluate the chemosensitizing effects of eribulin in the treatment-naïve setting.

Limitations of the study

We temporally evaluated clonal dynamics to determine whether eribulin treatment yielded drug-resistant cell subpopulations due to selection (of pre-existing drug-resistant subpopulations) or induction (of an altered chromatin accessibility/transcriptional state). The use of expressed genetic barcodes enabled multiplexed analysis with scRNA-seq and scATAC-seq profiles via QISSMET. Our observation that eribulin-resistant cells exhibited newly acquired states of chromatin accessibility and gene expression supported the notion that eribulin resistance was caused by an induction event (Figures 3 and S2). A limitation of this analysis was the lack of replicate populations of barcoded cells at each time point, which can provide a means of distinguishing clones with pre-existing vs. acquired drug resistance based on the detection of the same vs. different barcodes across replicates. Bhang et al.⁴⁴ used non-expressed genetic barcodes and found enrichment of overlapping subset of barcodes across replicate lung cancer cell populations following treatment with the EGFR inhibitor erlotinib, suggesting that such resistant cells were pre-existing and selected by drug treatment. Indeed, most erlotinib-resistant clones showed genomic amplification of *MET*,⁴⁴ a known cause of resistance to EGFR inhibitors.⁴⁵ Oren et al.⁴⁶ improved upon lineage tracing technology through the development of the Watermelon reporter system that uses expressed genetic barcodes. They found that lung cancer cell clones surviving treatment with the EGFR inhibitor osimertinib had pre-defined cell fates prior to drug treatment, and duplicate experiments showed enrichment of overlapping sets of barcodes suggesting drug selection.⁴⁶ Chang et al.¹³ used expressed barcodes to develop the method of tracking differential clonal responses by scRNA-seq (TraCe-seq) in lung cancer cells. Treatment of lung cancer cells with EGFR inhibitors yielded results

(G–N) NSG female mice bearing bilaterally implanted JAX-98^{naive} or NCCC-470^{NAC} orthotopic tumors were treated and assayed as in (A)–(F). After a 2-week treatment regimen (G and K), one tumor was resected from each mouse for molecular analysis (H and M). Mice were then maintained until an orthotopic tumor resumed growth and treated with a second round of therapy to assess tumor growth rate (I and L). Mice were maintained for an additional 3 months prior to tissue harvest to evaluate metastasis (J and N).

(O–Q) MDA-MB-231/Luc-ZsGreen cells were injected into the tail vein. Tumor burden was measured by bioluminescence imaging 2 weeks post injection (baseline) and after 2 weeks of drug treatment. Lung metastatic burden was quantified by counting metastases in H&E-stained sections.

Tumor volumes are shown as mean of 5 mice/group ± SEM. *p < 0.05, **p < 0.001, ***p < 0.0005, ****p < 0.0001 by Tukey-adjusted pairwise comparison.

analogous to those of Bhang et al.⁴⁴ with enrichment of overlapping subsets of barcodes across replicate experiments.^{13,44} Notably, all 3 of those studies used EGFR-mutant lung cancer cell lines sensitive to EGFR inhibition, where known resistance mechanisms often involve upregulation of compensatory kinase pathways.^{45,47} In contrast, our study used TNBC models and the cytotoxic chemotherapeutic eribulin. Thus, the type of drug and mechanism(s) of action likely dictates the path to resistance.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
 - Lead contact
 - Materials availability
 - Data and code availability
- **EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS**
 - Cell lines
 - Mouse models
 - Human tissue specimens
- **METHOD DETAILS**
 - Genetic constructs
 - *In vitro* drug treatment and IC₅₀ assays
 - Cell senescence, death, and apoptosis assays
 - Transwell cell migration assay
 - Cell monolayer scratch (wound closure) assay
 - Immunoblotting
 - Immunoprecipitation
 - Immunocytochemistry
 - Proteome integral solubility alteration (PISA) assay
 - RNA-seq
 - ATAC-seq
 - CUT&RUN
 - Massively parallel sequencing and bioinformatic analyses
 - Mouse tumor growth studies
 - Immunofluorescence staining of tissue sections
 - Multiplexed Tyramide signal amplification (TSA) staining
 - Lentivirus-mediated genetic barcoding of cells
 - Drug treatment of genetically barcoded cells
 - Single-cell/single-nucleus RNA-seq and ATAC-seq of genetically barcoded cells
 - Genetic barcode whitelist preparation
 - Single-cell/single-nucleus RNA-seq data analysis
 - Single-cell/single-nucleus ATAC-seq data analysis
 - Integration and genetic barcode classification in single-cell/single-nucleus seq
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.xcrm.2024.101504>.

ACKNOWLEDGMENTS

We thank the following Dartmouth Cancer Center Shared Resources: Genomics and Molecular Biology, DartLab Flow Cytometry, Pathology, and Mouse Modeling. We thank Dr. Meredith Brown, Jennifer Fields, and Dr. Radu Stan for technical assistance and helpful discussions and Dr. Robert A. Weinberg (Whitehead Institute) for critical reading of the manuscript. Funding was provided by a grant from METAvivor (to D.R.P.), a Prouty Pilot Grant from Friends of the Dartmouth Cancer Center (to D.R.P. and S.A.G.), The Elmer R. Pfefferkorn & Allan U. Munck Education and Research Fund (to D.R.P.), a Sponsored Research Agreement with Eisai, Inc. (D.R.P.), and NIH (P30CA023108, a Dartmouth Center for Quantitative Biology pilot grant from P20GM130454, S10OD025235, and R01GM122846 [to S.A.G.]; R00CA201574 [to D.R.P.]; R01CA267691 [to D.R.P. and T.W.M.]; and R01CA262232 [to T.W.M.]).

AUTHOR CONTRIBUTIONS

Conception and design, M.B. and D.R.P.; development of methodology, M.B., N.B.O., G.A.M., H.L., M.A.M.S., F.W.K., S.H.N., S.A.G., and D.R.P.; acquisition of data, M.B., G.A.M., N.B.O., H.L., I.S.L., S.A.G., F.W.K., and D.R.P.; analysis and interpretation of data M.B., N.B.O., G.A.M., M.A.M.S., S.D., H.L., F.W.K., O.M.W., I.L.C., S.H.N., K.E.M., S.A.G., T.W.M., and D.R.P.; writing, review, and/or editing of the manuscript, M.B., G.A.M., T.W.M., and D.R.P.; study supervision, D.R.P. and T.W.M.

DECLARATION OF INTERESTS

M.A.M.S. is an employee of Lifebytes India Pvt. Ltd. D.R.P. received research funding from Eisai Pharmaceutical Ltd.

Received: July 10, 2023

Revised: December 11, 2023

Accepted: March 19, 2024

Published: April 8, 2024

REFERENCES

1. Nieto, M.A., Huang, R.Y.J., Jackson, R.A., and Thiery, J.P. (2016). EMT: 2016. *Cell* 166, 21–45. <https://doi.org/10.1016/j.cell.2016.06.028>.
2. Shibue, T., and Weinberg, R.A. (2017). EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nat. Rev. Clin. Oncol.* 14, 611–629. <https://doi.org/10.1038/nrclinonc.2017.44>.
3. Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J.L., Vahdat, L.T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet* 377, 914–923. [https://doi.org/10.1016/S0140-6736\(11\)60070-6](https://doi.org/10.1016/S0140-6736(11)60070-6).
4. Smith, J.A., Wilson, L., Azarenko, O., Zhu, X., Lewis, B.M., Littlefield, B.A., and Jordan, M.A. (2010). Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. *Biochemistry* 49, 1331–1337. <https://doi.org/10.1021/bi901810u>.
5. Yoshida, T., Ozawa, Y., Kimura, T., Sato, Y., Kuznetsov, G., Xu, S., Uesugi, M., Agoulnik, S., Taylor, N., Funahashi, Y., and Matsui, J. (2014). Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. *Br. J. Cancer* 110, 1497–1505. <https://doi.org/10.1038/bjc.2014.80>.
6. Dybdal-Hargreaves, N.F., Risinger, A.L., and Mooberry, S.L. (2018). Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin. *Oncotarget* 9, 5545–5561. <https://doi.org/10.18632/oncotarget.23798>.
7. Kaul, R., Risinger, A.L., and Mooberry, S.L. (2019). Eribulin rapidly inhibits TGF-beta-induced Snail expression and can induce Slug expression in a

- Smad4-dependent manner. *Br. J. Cancer* 121, 611–621. <https://doi.org/10.1038/s41416-019-0556-9>.
8. Oba, T., and Ito, K.I. (2018). Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition. *Oncotarget* 9, 22986–23002. <https://doi.org/10.18632/oncotarget.25184>.
 9. Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H.L., and Weinberg, R.A. (2017). Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. *Cancer Res.* 77, 3982–3989. <https://doi.org/10.1158/0008-5472.CAN-16-3292>.
 10. Kröger, C., Afeyan, A., Mraz, J., Eaton, E.N., Reinhardt, F., Khodor, Y.L., Thiru, P., Bierie, B., Ye, X., Burge, C.B., and Weinberg, R.A. (2019). Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. *Proc. Natl. Acad. Sci. USA* 116, 7353–7362. <https://doi.org/10.1073/pnas.1812876116>.
 11. Pascual, T., Oliveira, M., Villagrasa, P., Ortega, V., Paré, L., Bermejo, B., Morales, S., Amillano, K., López, R., Galván, P., et al. (2021). Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. *NPJ Breast Cancer* 7, 145. <https://doi.org/10.1038/s41523-021-00351-4>.
 12. Brown, M.S., Abdollahi, B., Wilkins, O.M., Chakraborty, P., Ognjenovic, N.B., Muller, K.E., Jolly, M.K., Hassanpour, S., and Pattabiraman, D.R. (2021). Dynamic plasticity within the EMT spectrum, rather than static mesenchymal traits, drives tumor heterogeneity and metastatic progression of breast cancers. Preprint at bioRxiv 2021. <https://doi.org/10.1101/2021.03.17.434993>.
 13. Chang, M.T., Shanahan, F., Nguyen, T.T.T., Staben, S.T., Gazzard, L., Yamazoe, S., Wertz, I.E., Piskol, R., Yang, Y.A., Modrusan, Z., et al. (2022). Identifying transcriptional programs underlying cancer drug response with TraCe-seq. *Nat. Biotechnol.* 40, 86–93. <https://doi.org/10.1038/s41587-021-01005-3>.
 14. Emert, B.L., Cote, C.J., Torre, E.A., Dardani, I.P., Jiang, C.L., Jain, N., Shaffer, S.M., and Raj, A. (2021). Variability within rare cell states enables multiple paths toward drug resistance. *Nat. Biotechnol.* 39, 865–876. <https://doi.org/10.1038/s41587-021-00837-3>.
 15. Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D.M., Hill, A.J., Zhang, F., Mundlos, S., Christiansen, L., Steemers, F.J., et al. (2019). The single-cell transcriptional landscape of mammalian organogenesis. *Nature* 566, 496–502. <https://doi.org/10.1038/s41586-019-0969-x>.
 16. Qiu, X., Mao, Q., Tang, Y., Wang, L., Chawla, R., Pliner, H.A., and Trapnell, C. (2017). Reversed graph embedding resolves complex single-cell trajectories. *Nat. Methods* 14, 979–982. <https://doi.org/10.1038/nmeth.4402>.
 17. Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J., Livak, K.J., Mikkelsen, T.S., and Rinn, J.L. (2014). The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat. Biotechnol.* 32, 381–386. <https://doi.org/10.1038/nbt.2859>.
 18. Berest, I., Arnold, C., Reyes-Palomares, A., Palla, G., Rasmussen, K.D., Giles, H., Bruch, P.M., Huber, W., Dietrich, S., Helin, K., and Zaugg, J.B. (2019). Quantification of Differential Transcription Factor Activity and Multiomics-Based Classification into Activators and Repressors: diffTF. *Cell Rep.* 29, 3147–3159.e12. <https://doi.org/10.1016/j.celrep.2019.10.106>.
 19. Gaetani, M., Sabatier, P., Saei, A.A., Beusch, C.M., Yang, Z., Lundström, S.L., and Zubarev, R.A. (2019). Proteome Integral Solubility Alteration: A High-Throughput Proteomics Assay for Target Deconvolution. *J. Proteome Res.* 18, 4027–4037. <https://doi.org/10.1021/acs.jproteome.9b00500>.
 20. Sánchez-Tilló, E., Lázaro, A., Torrent, R., Cuatrecasas, M., Vaquero, E.C., Castells, A., Engel, P., and Postigo, A. (2010). ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. *Oncogene* 29, 3490–3500. <https://doi.org/10.1038/onc.2010.102>.
 21. Liu, L., Tong, Q., Liu, S., Cui, J., Zhang, Q., Sun, W., and Yang, S. (2016). ZEB1 Upregulates VEGF Expression and Stimulates Angiogenesis in Breast Cancer. *PLoS One* 11, e0148774. <https://doi.org/10.1371/journal.pone.0148774>.
 22. Debnath, P., Huiem, R.S., Dutta, P., and Palchoudhuri, S. (2022). Epithelial-mesenchymal transition and its transcription factors. *Biosci. Rep.* 42. <https://doi.org/10.1042/BSR20211754>.
 23. Christenson, J.L., Butterfield, K.T., Spoelstra, N.S., Norris, J.D., Josan, J.S., Pollock, J.A., McDonnell, D.P., Katzenellenbogen, B.S., Katzenellenbogen, J.A., and Richer, J.K. (2017). MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. *Horm. Cancer* 8, 69–77. <https://doi.org/10.1007/s12672-017-0285-6>.
 24. Hüsemann, Y., Geigl, J.B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., Forni, G., Eils, R., Fehm, T., Riethmüller, G., and Klein, C.A. (2008). Systemic spread is an early step in breast cancer. *Cancer Cell* 13, 58–68. <https://doi.org/10.1016/j.ccr.2007.12.003>.
 25. Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al. (2012). EMT and dissemination precede pancreatic tumor formation. *Cell* 148, 349–361. <https://doi.org/10.1016/j.cell.2011.11.025>.
 26. Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., and Lander, E.S. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* 138, 645–659. <https://doi.org/10.1016/j.cell.2009.06.034>.
 27. Ognjenovic, N.B., Bagheri, M., Mohamed, G.A., Xu, K., Chen, Y., Mohamed Saleem, M.A., Brown, M.S., Nagaraj, S.H., Muller, K.E., Gerber, S.A., et al. (2020). Limiting Self-Renewal of the Basal Compartment by PKA Activation Induces Differentiation and Alters the Evolution of Mammary Tumors. *Dev. Cell* 55, 544–557.e6. <https://doi.org/10.1016/j.devcel.2020.10.004>.
 28. Pattabiraman, D.R., Bierie, B., Kober, K.I., Thiru, P., Krall, J.A., Zill, C., Reinhardt, F., Tam, W.L., and Weinberg, R.A. (2016). Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. *Science* 351, aad3680. <https://doi.org/10.1126/science.aad3680>.
 29. Ocaña, O.H., Córcoles, R., Fabra, A., Moreno-Bueno, G., Acloque, H., Vega, S., Barrallo-Gimeno, A., Cano, A., and Nieto, M.A. (2012). Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prx1. *Cancer Cell* 22, 709–724. <https://doi.org/10.1016/j.ccr.2012.10.012>.
 30. Tsai, J.H., Donaher, J.L., Murphy, D.A., Chau, S., and Yang, J. (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. *Cancer Cell* 22, 725–736. <https://doi.org/10.1016/j.ccr.2012.09.022>.
 31. Bierie, B., Pierce, S.E., Kroeger, C., Stover, D.G., Pattabiraman, D.R., Thiru, P., Liu Donaher, J., Reinhardt, F., Chaffer, C.L., Keckesova, Z., and Weinberg, R.A. (2017). Integrin-beta4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. *Proc. Natl. Acad. Sci. USA* 114, E2337–E2346. <https://doi.org/10.1073/pnas.1618298114>.
 32. Dongre, A., Rashidian, M., Eaton, E.N., Reinhardt, F., Thiru, P., Zagorulya, M., Nepal, S., Banaz, T., Martner, A., Spranger, S., and Weinberg, R.A. (2021). Direct and Indirect Regulators of Epithelial-Mesenchymal Transition-Mediated Immunosuppression in Breast Carcinomas. *Cancer Discov.* 11, 1286–1305. <https://doi.org/10.1158/2159-8290.CD-20-0603>.
 33. Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., et al. (2018). Identification of the tumour transition states occurring during EMT. *Nature* 556, 463–468. <https://doi.org/10.1038/s41586-018-0040-3>.
 34. Vijay, G.V., Zhao, N., Den Hollander, P., Toneff, M.J., Joseph, R., Pietila, M., Taube, J.H., Sarkar, T.R., Ramirez-Pena, E., Werden, S.J., et al. (2019). GSK3beta regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. *Breast Cancer Res.* 21, 37. <https://doi.org/10.1186/s13058-019-1125-0>.

35. Jolly, M.K., Boareto, M., Huang, B., Jia, D., Lu, M., Ben-Jacob, E., Onuchic, J.N., and Levine, H. (2015). Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. *Front. Oncol.* 5, 155. <https://doi.org/10.3389/fonc.2015.00155>.
36. Lüönd, F., Sugiyama, N., Bill, R., Bornes, L., Hager, C., Tang, F., Santacroce, N., Beisel, C., Ivanek, R., Bürglin, T., et al. (2021). Distinct contributions of partial and full EMT to breast cancer malignancy. *Dev. Cell* 56, 3203–3221.e11. <https://doi.org/10.1016/j.devcel.2021.11.006>.
37. Boumahdi, S., and de Sauvage, F.J. (2020). The great escape: tumour cell plasticity in resistance to targeted therapy. *Nat. Rev. Drug Discov.* 19, 39–56. <https://doi.org/10.1038/s41573-019-0044-1>.
38. Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada, L.F. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* 488, 522–526. <https://doi.org/10.1038/nature11287>.
39. Diehn, M., Cho, R.W., Lobo, N.A., Kalisky, T., Dorie, M.J., Kulp, A.N., Qian, D., Lam, J.S., Ailles, L.E., Wong, M., et al. (2009). Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature* 458, 780–783. <https://doi.org/10.1038/nature07733>.
40. Postigo, A.A., and Dean, D.C. (1999). ZEB represses transcription through interaction with the corepressor CtBP. *Proc. Natl. Acad. Sci. USA* 96, 6683–6688. <https://doi.org/10.1073/pnas.96.12.6683>.
41. Wang, J., Scully, K., Zhu, X., Cai, L., Zhang, J., Prefontaine, G.G., Kronos, A., Ohgi, K.A., Zhu, P., Garcia-Bassets, I., et al. (2007). Opposing LSD1 complexes function in developmental gene activation and repression programmes. *Nature* 446, 882–887. <https://doi.org/10.1038/nature05671>.
42. Aghdassi, A., Sendler, M., Guenther, A., Mayerle, J., Behn, C.O., Heidecke, C.D., Friess, H., Büchler, M., Evert, M., Lerch, M.M., and Weiss, F.U. (2012). Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. *Gut* 61, 439–448. <https://doi.org/10.1136/gutjnl-2011-300060>.
43. Meidhof, S., Brabletz, S., Lehmann, W., Preca, B.T., Mock, K., Ruh, M., Schüler, J., Berthold, M., Weber, A., Burk, U., et al. (2015). ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. *EMBO Mol. Med.* 7, 831–847. <https://doi.org/10.15252/emmm.201404396>.
44. Bhang, H.e.C., Ruddy, D.A., Krishnamurthy Radhakrishna, V., Caushi, J.X., Zhao, R., Hims, M.M., Singh, A.P., Kao, I., Rakiec, D., Shaw, P., et al. (2015). Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. *Nat. Med.* 21, 440–448. <https://doi.org/10.1038/nm.3841>.
45. Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N., Gale, C.M., Zhao, X., Christensen, J., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 316, 1039–1043. <https://doi.org/10.1126/science.1141478>.
46. Oren, Y., Tsabar, M., Cuoco, M.S., Amir-Zilberstein, L., Cabanos, H.F., Hütter, J.C., Hu, B., Thakore, P.I., Tabaka, M., Fulco, C.P., et al. (2021). Cycling cancer persister cells arise from lineages with distinct programs. *Nature* 596, 576–582. <https://doi.org/10.1038/s41586-021-03796-6>.
47. Sattler, M., Mambetsariev, I., Fricke, J., Tan, T., Liu, S., Vaidehi, N., Pisick, E., Mirzapiozova, T., Rock, A.G., Merla, A., et al. (2023). A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. *J. Clin. Med.* 12, 1936. <https://doi.org/10.3390/jcm12051936>.
48. Guy, C.T., Cardiff, R.D., and Muller, W.J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol. Cell Biol.* 12, 954–961. <https://doi.org/10.1128/mcb.12.3.954-961.1992>.
49. Wiederschain, D., Wee, S., Chen, L., Loo, A., Yang, G., Huang, A., Chen, Y., Caponigro, G., Yao, Y.M., Lengauer, C., et al. (2009). Single-vector inducible lentiviral RNAi system for oncology target validation. *Cell Cycle* 8, 498–504. <https://doi.org/10.4161/cc.8.3.7701>.
50. Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., and Zhang, F. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* 343, 84–87. <https://doi.org/10.1126/science.1247005>.
51. Grassetti, A.V., Hards, R., and Gerber, S.A. (2017). Offline pentafluorophenyl (PFP)-RP prefractionation as an alternative to high-pH RP for comprehensive LC-MS/MS proteomics and phosphoproteomics. *Anal. Bioanal. Chem.* 409, 4615–4625. <https://doi.org/10.1007/s00216-017-0407-6>.
52. Eng, J.K., Jahan, T.A., and Hoopmann, M.R. (2013). Comet: an open-source MS/MS sequence database search tool. *Proteomics* 13, 22–24. <https://doi.org/10.1002/pmic.201200439>.
53. Elias, J.E., and Gygi, S.P. (2007). Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. *Nat. Methods* 4, 207–214. <https://doi.org/10.1038/nmeth1019>.
54. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9, 357–359. <https://doi.org/10.1038/nmeth.1923>.
55. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079. <https://doi.org/10.1093/bioinformatics/btp352>.
56. Tarasov, A., Vilella, A.J., Cuppen, E., Nijman, I.J., and Prins, P. (2015). Sambamba: fast processing of NGS alignment formats. *Bioinformatics* 31, 2032–2034. <https://doi.org/10.1093/bioinformatics/btv098>.
57. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550. <https://doi.org/10.1186/s13059-014-0550-8>.
58. Zheng, G.X.Y., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B., Wheeler, T.D., McDermott, G.P., Zhu, J., et al. (2017). Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* 8, 14049. <https://doi.org/10.1038/ncomms14049>.
59. Satpathy, A.T., Granja, J.M., Yost, K.E., Qi, Y., Meschi, F., McDermott, G.P., Olsen, B.N., Mumbach, M.R., Pierce, S.E., Corces, M.R., et al. (2019). Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. *Nat. Biotechnol.* 37, 925–936. <https://doi.org/10.1038/s41587-019-0206-z>.
60. Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd, Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. *Cell* 177, 1888–1902.e21. <https://doi.org/10.1016/j.cell.2019.05.031>.
61. Farahpour, F., Saeedghalati, M., and Hoffmann, D. (2016). MullerPlot: Generates Muller Plot from Population/Abundance/Frequency Dynamics Data. <https://cran.r-project.org/package=MullerPlot>.
62. Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baiglaenko, Y., Brenner, M., Loh, P.R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat. Methods* 16, 1289–1296. <https://doi.org/10.1038/s41592-019-0619-0>.
63. McGinnis, C.S., Patterson, D.M., Winkler, J., Conrad, D.N., Hein, M.Y., Sri-vastava, V., Hu, J.L., Murrow, L.M., Weissman, J.S., Werb, Z., et al. (2019). MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. *Nat. Methods* 16, 619–626. <https://doi.org/10.1038/s41592-019-0433-8>.
64. Tang, M., Kaymaz, Y., Logeman, B.L., Eichhorn, S., Liang, Z.S., Dulac, C., and Sackton, T.B. (2021). Evaluating single-cell cluster stability using the Jaccard similarity index. *Bioinformatics* 37, 2212–2214. <https://doi.org/10.1093/bioinformatics/btaa956>.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
APC anti-mouse CD326 (Ep-CAM)	BioLegend	Cat #118214; RRID:AB_1134102
anti-E-cadherin	BD Biosci.	Cat #610182; RRID:AB_397581
anti-E-cadherin	Cell Sig. Tech.	Cat #3195; RRID:AB_2291471
anti-Vimentin	Cell Sig. Tech.	Cat #5741; RRID:AB_10695459
anti-Snail	Cell Sig. Tech.	Cat #3879; RRID:AB_2255011
anti-Snail	Cell Sig. Tech.	Cat #3895; RRID:AB_2191759
anti-Tubulin	Cell Sig. Tech.	Cat #5666; RRID:AB_10691594
anti-Gapdh	Cell Sig. Tech.	Cat #2118; RRID:AB_561053
anti-Zeb1	Bethyl	Cat #A301-922A; RRID:AB_1524126
anti-Smarcd1	ThermoFisher	Cat #PA5-52049; RRID:AB_2647616
anti-Smarcc1	Bethyl Laborat.	Cat #A301-020A; RRID:AB_817978
anti-Smarcc1	Cell Sig. Tech.	Cat #11956; RRID:AB_2797776
anti-Smarcd3	Cell Sig. Tech.	Cat #62265; RRID:AB_2799624
anti-H3K4me3	ThermoFisher	Cat #MA5-11199; RRID:AB_10977872
anti-H3K27me3	ThermoFisher	Cat #MA5-11198; RRID:AB_11000749
anti-CD104APC	BioLegend	Cat #123612; RRID:AB_2734181
anti-CD44PECy7	BioLegend	Cat #858802; RRID:AB_2801225
anti-KRT8	ThermoFisher	Cat #PA5-29607; RRID:AB_2547083
anti-KRT14	ThermoFisher	Cat #MA5-11599; RRID:AB_10982092
Biological samples		
Human FFPE TNBC tissue specimens	SOLTI-1007-NeoEribulin study	N/A
Human FFPE TNBC tissue specimens	Dartmouth-Hitchcock Medical Center Dept. of Pathology	N/A
Chemicals, peptides, and recombinant proteins		
VivoGlo Luciferin	Promega	Cat #P1043
Eribulin	Eisai Pharm. Inc.	(via Material Transfer Agreem.)
Vinorelbine	SAGENT	NDC 25021-204-01
Paclitaxel	Hospira	NDC 61703-342-09
Critical commercial assays		
SA-bGal kit	Cell Sig. Tech.	Cat #23833
LIVE/DEAD Viability/Cytotoxicity Kit	Invitrogen	Cat #L3224
Universal Magnetic Co-Ip kit	Active Motif	Cat #54002
Deposited data		
RNA-seq, ATAC-seq, CUT&RUN, single-cell RNA-seq data	This paper	GEO: GSE207482 and GSE207773
Experimental models: Cell lines		
PB3	Robert Weinberg Lab	N/A
MDA-MB-231	Robert Weinberg Lab	RRID:CVCL_0062
SUM-159	Robert Weinberg Lab	RRID:CVCL_5423
Experimental models: Organisms/strains		
MMTV-PyMT transgenic mice	Jackson Laboratory	Cat #022974; RRID:IMSR_JAX:022974
NOD/SCID/IL2Rg ^{-/-} (NSG) mice	Jackson Laboratory	Cat #005557; RRID:IMSR_JAX:005557

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Recombinant DNA		
Plasmid psPAX2	Addgene	Cat #12260; RRID:Addgene_12260
Plasmid pMD2.G	Addgene	Cat #12259; RRID:Addgene_12259
Plasmid, lentiviral transfer, encoding <i>SMARCD1</i>	Genecopoeia	Cat #EX-A1760-LX304
Plasmid Tet-pLKO-puro	Addgene	Cat #21915; RRID:Addgene_21915
Plasmid Lenti-CRISPR V2	Addgene	Cat #52961; RRID:Addgene_52961
Plasmid pHIV-Luc-ZsGreen	Addgene	Cat #39196; RRID:Addgene_39196
Software and algorithms		
Tutorial and original code	This paper	https://github.com/lifebytes/bagheri-et-al_scRNA-ATAC_analysis
Other		
CUTANA CUT&RUN Kit	EpiCypher	Cat #14-1048
RNeasy plus kit	Qiagen	Cat #74134
QIAamp DNA isolation kit	Qiagen	Cat #51304
MinElute Purification Kit	Qiagen	Cat #28004
ProLong™ Diamond Antifade Mountant	ThermoFisher	Cat #P36961

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Todd Miller (tomiller@mcw.edu).

Materials availability

Plasmids and cell lines generated in this study are available from the [lead contact](#) with a completed Materials Transfer Agreement.

Data and code availability

The raw and analyzed RNA-seq, ATAC-seq, CUT&RUN, and single-cell RNA-seq data were deposited in the NCBI Gene Expression Omnibus at accession numbers GSE207482 and GSE207773, which are publicly available. The tutorial and original code are available at:

https://github.com/lifebytes/bagheri-et-al_scRNA-ATAC_analysis. Original immunoblot and microscopy data reported in this paper will be shared by the [lead contact](#) upon request. Any additional information required to reanalyze the data reported in this paper is available from the [lead contact](#).

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Cell lines

MMTV-PyMT murine mammary tumor-derived PB3 cells, and human MDA-MB-231 and SUM-159 breast cancer cells were gifts from Dr. Bob Weinberg (Whitehead Institute for Biomedical Research). PB3 cells were maintained in DMEM/F12 medium supplemented with 5% adult bovine serum (ABS), 2 mM L-Glutamine, and 1X MEM Non-Essential Amino Acids Solution (ThermoFisher Scientific cat. #11140050). MDA-MB-231 and SUM-159 cells were maintained in DMEM and F12 medium, respectively, supplemented with 10% fetal bovine serum (FBS). Cell lines were propagated for <4 months following authentication by STR genotyping, and were confirmed to be mycoplasma-negative.

Mouse models

Animal studies were approved by the Dartmouth College Institutional Animal Care and Use Committee. MMTV-PyMT transgenic mice [(Tg(MMTV-PyVT)634Mul/LelJ mice on a C57Bl/6 J background, strain #022974, ref. ⁴⁸] were obtained from the Jackson Laboratory and bred in-house. Female 8-to-10-week-old NOD/SCID/IL2R $\gamma^{-/-}$ (NSG) mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, strain #005557) were obtained from the Dartmouth Cancer Center Mouse Modeling Shared Resource.

Human tissue specimens

Human FFPE TNBC tissue specimens were obtained from two sources: the SOLTI-1007-NeoEribulin study¹¹; Dartmouth-Hitchcock Medical Center pathology archives. SOLTI-1007-NeoEribulin was done in accordance with Good Clinical Practice guidelines and the

Declaration of Helsinki. That study protocol was approved by independent ethics committees at each center and the Agencia Española de Medicamentos y Productos Sanitarios. All patients provided written informed consent. Specimens from Dartmouth-Hitchcock Medical Center were obtained through clinically indicated procedures for diagnostic purposes. Use of these specimens for this research was approved the Dartmouth Health Human Research Protection Program (STUDY02000731).

METHOD DETAILS

Genetic constructs

Lentiviral particles were produced using standard protocols. Briefly, HEK293T cells were transfected with transfer plasmid and packaging plasmids psPAX2 (Addgene #12260) and pMD2.G (Addgene #12259) using Lipofectamine 3000 (ThermoFisher Scientific cat. #L3000015). Lentiviral particles were concentrated using Lenti-X Concentrator (Takara Bio, cat. #631232), and cancer cells were transduced with lentivirus in the presence of polybrene (8–30 $\mu\text{g}/\text{mL}$).

A lentiviral transfer plasmid encoding *SMARCD1* cDNA was purchased from GeneCopoeia (cat. #EX-A1760-LX304) and used to generate lentivirus to transduce PB3 and MDA-MB-231 cells; stably transfected cells were selected with 10 $\mu\text{g}/\text{mL}$ blasticidin for 7 days. shRNA constructs were designed and synthesized by IDT and cloned into the Tet-pLKO-puro transfer plasmid (Addgene plasmid #21915) as described.⁴⁹ CRISPR/Cas9 sgRNAs were designed and synthesized by IDT and cloned into the pLenti-CRISPR V2 transfer plasmid (Addgene plasmid #52961) as described.⁵⁰ To trace metastasis *in vivo*, MDA-MB-231 cells were stably transfected with lentivirus generated using the pHIV-Luc-ZsGreen transfer plasmid encoding fluorescent ZsGreen and firefly luciferase (Addgene #39196); stably expressing cells were collected by FACS for ZsGreen fluorescence.

In vitro drug treatment and IC₅₀ assays

Stock solutions for eribulin and vinorelbine (10 mM) were prepared using water, and paclitaxel was prepared using DMSO. Cells were plated in 96-well white-walled, clear, flat-bottom microplates at a density of 7×10^3 cells/well in 100 μL growth medium. Twenty-four hours later, cells were treated with dose ranges of drugs. Ten μL resazurin (Alamar blue, 0.2 mg/mL, ThermoFisher Scientific cat. #R12204) was added to each well for 4 h at 37°C, and Abs₅₉₀ was measured to reflect cell viability. IC₅₀ was determined for each drug using nonlinear regression in Prism software (Graphpad).

Cell senescence, death, and apoptosis assays

Senescence-associated β -galactosidase activity was evaluated using CellEvent Senescence Green Flow Cytometry Assay Kit (ThermoFisher Scientific cat. #C10841). Cells were treated with drugs as indicated, trypsinized, washed with 1X PBS, resuspended in 100 μL fixation solution, and incubated for 10 min at room temp. Then cells were washed in 1% BSA in PBS to remove fixation solution, resuspended in 100 μL working solution, and incubated for 2 h at 37°C (atmospheric CO₂). Cells were resuspended in 1% BSA in PBS and analyzed by flow cytometry.

Cell death and apoptosis were measured using the Dead Cell Apoptosis Kit (ThermoFisher Scientific cat. #V35114). Cells were treated with drugs as indicated for 72 h, harvested, and washed in 1X Annexin binding buffer. Cells were collected by centrifugation, resuspended in 1X Annexin binding buffer, and stained with SYTOX Green, resazurin, and APC-Annexin V. Cells were incubated at 37°C with 5% CO₂ for 15 min. Then 400 μL of 1X annexin-binding buffer was added to samples, and cells were analyzed by flow cytometry. Data were analyzed with FlowJo software (BD Biosciences).

Transwell cell migration assay

Invasion capabilities of cells were measured using 24-well Transwell permeable polycarbonate membrane supports with 8- μm pores. The tops of Transwell membranes were treated with Matrigel (Corning cat. #CLS354234) for 3 h at room temperature. Cells suspended in serum-free medium (10^5 cells/mL) were seeded on top of Transwell chambers (0.4 mL/chamber). The lower chamber contained growth medium with 10% FBS. At 8 h after cell seeding, non-invaded cells were removed from the top of the membrane using a cotton swab. Cells were fixed using 4% paraformaldehyde and stained with 0.1% crystal violet. Cells that had invaded through the membrane to the bottom were counted manually by microscopy.

Cell monolayer scratch (wound closure) assay

Migration capabilities of cells were assessed using a scratch assay. Cells were seeded into 6-well tissue culture plates (5×10^5 cells/well to provide near-confluent monolayers) and incubated overnight at 37°C. Scratch wounds were created in monolayers by dragging a sterile 100- μL plastic pipette tip across the plate. Wells were washed with PBS to remove debris. Cells were incubated in growth medium at 37°C with 5% CO₂ and imaged after 2, 4, 8, and 16 h. Cell migration was measured as the relative amount of closure of the scratch/wound.

Immunoblotting

Cells were lysed in cold RIPA buffer (ThermoFisher Scientific cat. #89901) supplemented with phosphatase/protease inhibitors (ThermoFisher Scientific cat. #78446) for 1 h on ice. Lysates were centrifuged at 20,000 $\times g$ for 10 min at 4°C, and supernatant was analyzed by Quick Start Bradford Protein Assay kit (BIO-RAD cat. #5000202). Lysates were diluted with NuPAGE LDS sample

buffer (Life Technologies cat. #NP0007) and NuPAGE Sample Reducing Agent (Life Technologies cat. #NP0009). Samples were heated at 72°C before resolving on 4–12% Bis-Tris gradient gels. Protein was transferred to nitrocellulose using either MiniBlot module or iBlot2 Gel Transfer Device (ThermoFisher Scientific cat. #B1000 and #IB21001). Membranes were blocked with 2.5% BSA or 2.5% non-fat dry milk, and then incubated overnight with primary antibodies in TBST (TBS supplemented with 0.1% Tween 20). HRP-conjugated secondary antibodies were incubated with membranes at room temp. with agitation for 1 h in blocking buffer. Membranes were developed using SuperSignal Western Blot Substrate (ThermoFisher Scientific cat. # A45915).

Immunoprecipitation

Cells were seeded in 150-mm dishes and treated +/– eribulin for 48 h. Nuclear fractions were extracted with the Universal Magnetic co-IP kit (Active Motif cat #54002). One mg of protein in lysate was mixed with 5 µg antibody and protein G magnetic beads. Immunoprecipitates were analyzed by western blot.

Immunocytochemistry

Eight-chamber cell culture slides (BD Falcon) with pretreated with poly-L-lysine (Gibco cat. #A3890401). Cells (5×10^3 per chamber) were seeded onto slides and treated as indicated. Cells were rinsed with cold PBS and fixed with 4% paraformaldehyde or cold acetone-methanol (1:1) for 10 min at room temp., followed by permeabilization with 0.1% Triton X-100. Cells were treated with blocking buffer recommended by the manufacturer of each primary antibody for 1 h at room temp. followed by primary antibody incubation overnight at 4°C. Cells were washed with cold PBS three times for 3 min each, and then incubated with Alexa 555-labeled anti-rabbit and Alexa 488-labeled anti-mouse secondary antibodies (ThermoFisher Scientific cat. # A-11001) at room temp. for 1 h. Cells were washed three times with cold PBS. Cells were analyzed by fluorescence confocal microscopy.

Proteome integral solubility alteration (PISA) assay

PISA assay was performed as described¹⁹ with the following modifications. PB3 cells were cultured in 10-cm dishes in triplicate and treated with DMSO (vehicle), 300 nM eribulin, or 600 nM eribulin for 4 h. Cells were harvested by trypsinization, washed with PBS, and resuspended in PBS to a cell density equivalent to 0.4 mg protein/mL. One-hundred µL of each cell suspension was split among nine replicate 0.2-mL tubes, followed by incubation at 9 different temperatures across a gradient of 34°C–42°C for 3 min in a thermocycler. Samples were snap-frozen in liquid nitrogen, and then thawed at room temperature for 5 min in a water bath. This freeze/thaw process was repeated twice, followed by centrifugation at 21,000 x g at 4°C for 10 min. Fifty µL of supernatant from each temperature condition was transferred to a new 1.5-mL tube, followed by the addition of 1 mL of a solution containing 9 M urea/50 mM Tris pH 8.1/150 mM NaCl/2 mM DTT. Mixtures were heated at 45°C for 15 min, followed by alkylation with 7 mM iodoacetamide for 1 h in the dark. The alkylation reaction was quenched with DTT (2 mM final conc.) for 15 min, followed by dilution in 1.5 mL 50 mM Tris pH 8.1/150 mM NaCl and digestion with 1 mg sequencing-grade trypsin overnight at 30°C. Each sample was desalted on an OASIS mHLB plate (2 mg sorbent). Peptide concentrations were quantified by BCA assay (ThermoFisher Scientific cat. #23225). The equivalent of 40 mg of peptide from each replicate of each temperature condition was labeled using unique isobaric labeling tags (TMT 10-plex reagents, ThermoFisher Scientific cat. # EPX140-40040-901) by resuspension in 30 µg of 166 mM EPPS pH 9 and addition of TMT reagent (80 µg reagent in 8 µL dry acetonitrile) for 1 h, followed by quenching with 1% hydroxylamine for 20 min at room temperature. Each multiplex sample was combined in a single 1.5-mL tube, followed by the addition of 600 µL 1% TFA and desalting on an OASIS C18 plate (10 mg sorbent). The desalted multiplex was dried by vacuum centrifugation and separated on a pentafluorophenyl (PFP) reverse-phase column (Waters) into 48 distinct fractions,⁵¹ concatenated into 16 combined fractions by sequential addition, dried by vacuum centrifugation, and analyzed by LC-MS/MS on a Proxeon Easy-nLC 1200-Orbitrap Fusion Lumos mass spectrometer platform using SPS-MS3-based quantification. The resulting tandem mass spectra were data-searched using the Comet algorithm⁵² against the human UniProt database (www.uniprot.org), filtered to a 1% false discovery rate using the target-decoy strategy.⁵³ Quantification was accomplished using in-house software to extract reporter ion intensities per-peptide and summed across all peptides for each unique UniProt identifier. Each channel was normalized across all proteins to the total intensity of the least abundant channel, and protein intensities were adjusted accordingly. Final protein stability ratios were reported as ΔSm values as described.¹⁹

RNA-seq

Cells were washed twice and harvested in PBS. Total RNA was extracted using RNeasy Plus Mini Kit (Qiagen cat. #74136). Purified RNA was used for reverse transcription with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems cat. #4374967): 1.5 µg RNA was used in a 20-µL reaction and incubated at 25°C for 10 min, and then at 37°C for 120 min. Reverse transcriptase was inactivated by heating to 85°C for 5 min cDNA was used for library preparation (Roche, Kapa mRNA HyperPrep Kit cat. #KR1351) and massively parallel sequencing on an Illumina NextSeq500. RNA-seq data were analyzed as described previously.¹²

ATAC-seq

Methodology was adapted from ref. ¹. Cells were washed with cold PBS and trypsinized. Cells (10^5) were resuspended in cold PBS and centrifuged at 500 x g for 5 min. Cells were resuspended in 1 mL cold ATAC-seq resuspension buffer (RSB: 10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl₂ in water) and centrifuged at 4 °C at 500 x g for 5 min. Nuclei were isolated by resuspending cells in

100 μ L ATAC-seq lysis buffer (RSB plus 0.1% NP40, 0.1% Tween 20, 0.01% digitonin) by pipetting up and down 5 times. Cells suspensions were incubated on ice for 3 min and washed with 1 mL ATAC-seq RSB containing 0.1% Tween 20. Suspensions were centrifuged at 4 °C at 500 \times *g* for 10 min. Supernatant was removed and discarded, and pelleted nuclei were resuspended in 100 μ L Transposition Mix (50 μ L 2 \times TD buffer, 5 μ L transposase (100 nM final conc.), 33 μ L PBS, 1 μ L 1% digitonin, 1 μ L 10% Tween 20, 10 μ L water). Transposition reactions were incubated at 37°C for 30 min in a thermomixer with shaking at 1,000 rpm. DNA was analyzed by massively parallel sequencing on an Illumina NextSeq500. ATAC-seq data were analyzed as described.¹²

CUT&RUN

CUT&RUN was performed using CUTANA Kit (EpiCypher cat. #14–1048) per manufacturer's recommendations with minor modifications. Cells (5×10^5) were washed with PBS and bound to concanavalin A-coated magnetic beads. Cells were permeabilized with Wash Buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM spermidine, and 1 \times Roche EDTA-free Complete Protease Inhibitor) containing 0.025% digitonin (Digitonin Buffer) and 2 mM EDTA, and incubated with primary antibody (anti-ZEB1, anti-H3K4me3, or IgG isotype control) overnight at 4°C. The cell-bead slurry was washed twice with Digitonin Buffer and incubated with 1 \times Protein-A/G-MNase (pAG-MNase) in Digitonin Buffer for 10 min at room temp. The slurry was washed twice with Digitonin Buffer, and incubated in Digitonin Buffer containing 2 mM CaCl₂ for 2 h at 4°C to activate pAG-MNase digestion. Digestion was stopped by addition of 2 \times Stop Buffer (340 mM NaCl, 20 mM EDTA, 4 mM EGTA, 50 μ g/mL RNase A, 50 μ g/mL glycogen), and sample was incubated for 10 min at 37°C to release chromatin into supernatant and degrade RNA. Supernatant was recovered, and DNA was isolated using MinElute Reaction Cleanup Kit (Qiagen cat. #28206). Isolated CUT&RUN DNA fragments were quantified by Qubit, and 5–10 ng DNA was used for library preparation with the NEB Ultra II DNA Kit. Library amplification was performed using the modified PCR cycling conditions described in Step 39 of the EpiCypher CUTANA (EpiCypher) protocol. Barcoded libraries were pooled for sequencing on a NextSeq500 (Mid Output flow cell, 10 million 50-bp paired-end reads per sample).

Massively parallel sequencing and bioinformatic analyses

Raw sequence quality of reads was determined using FastQC (v0.11.9). Reads were trimmed using Cutadapt (v2.4) for adapter sequences with parameters “–nextseq-trim 20 –max-n 0.8 –trim-n -m 1”. Reads were mapped to hg38 genome (for human samples) or mm10 genome (for murine samples) using Bowtie2 (v2.4.2)⁵⁴ with parameters “–local –no-mixed –no-discordant.” Alignments sorted with samtools (v1.11),⁵⁵ and unmapped or multi-mapping reads were filtered using sambamba (v0.8.0).⁵⁶ MarkDuplicates (Picard Tools) was used to identify and remove duplicate reads. Normalized signal tracks were generated using deepTools (v 3.3.0) command BamCoverage with parameters “–binSize 20 –smoothLength 60 –normalizeUsing CPM –centerReads –extendReads.” Command “bamPEFragmentSize” (deepTools) was used to confirm expected fragment length distributions were present in each sample, and plotFingerprint was used to confirm genomic enrichment in target-captured samples over corresponding IgG controls. Peaks were called using the MACS2 (v2.2.7.1) “call peak” command in narrowpeak mode with parameters “–f BAMPE –keep-dup all –q 0.05.” Corresponding target-captured controls were specified using option –c. Effective genome size was provided using option –g with a value of 2913022398 for human data, and 2652783500 for mouse data. Target capture signal was assessed using Fraction of Reads in Peaks (FRiP) calculated for each sample. Called peaks were filtered against the ENCODE human blacklist (human: ENCF356LFX, mouse: ENCF547MET) and further restricted to peaks demonstrating a 2-fold or greater signal increase relative to IgG controls. Reproducible peak sets were identified for replicate pairs using BEDTools (v 2.30.0) command “intersect” with parameter “–a.” Peak sets were annotated using the *annotatePeak()* function (ChIPseeker package in R software). Promoters were defined as transcriptional start sites (TSS) \pm 1 kb. The R packages “TxDb.Hsapiens.UCSC.hg38.knownGene” and “TxDb.Mmusculus.UCSC.mm10.knownGene” were used to define genomic features for human and mouse peaks, respectively. Any peaks >10 kb from the closest gene were annotated as “intergenic” peaks. A consensus peak set was generated by merging overlapping peaks called across all samples. Read counts in each consensus peak region were counted from BAM files using the featureCounts() function (Rsubread package) with options “isPairedEnd = TRUE, countMultiMappingReads = FALSE”. DESeq2⁵⁷ was used to perform differential binding analysis on the matrix of read counts from consensus peak regions. Adequate dispersion trends were confirmed during model fitting for all analyses. A Benjamini-Hochberg adjusted p value threshold of <0.05 (Wald-test) was used to denote statistically significant peaks.

Mouse tumor growth studies

JAX-98 and JAX-91 PDX models were purchased from The Jackson Laboratory (cat. # TM00098 and TM00091). NCI-140-R was obtained from the NCI Patient-Derived Models Repository (cat. # 994819). NCCC-470 was obtained from the Dartmouth Cancer Center Mouse Modeling Shared Resource. All PDX models were derived from primary tumor surgical specimens. JAX-98 and NCI-140-R were derived from treatment-naïve patients. NCCC-470 and JAX-91 were derived from patients following treatment with neoadjuvant chemotherapy.

PDX tumors were subcutaneously engrafted into female 8-to-10-week-old NSG mice. When tumor volumes reached \sim 1500 mm³, tumors were harvested and washed with cold PBS containing antibiotics [penicillin (100 U/mL), streptomycin (100 μ g/mL), amphotericin B (0.25 μ g/mL)]. Tumors were sliced into 5-mm³ fragments and either cryopreserved or serially engrafted into the inguinal mammary fat pads of NSG female mice for experimentation.

Female heterozygous MMTV-PyMT mice were monitored for mammary tumor occurrence by palpation. Tumor dimensions were measured twice weekly with a digital caliper, and volume was calculated as $\text{Length} \times \text{Width}^2/2$. MMTV-PyMT mice with a tumor $\geq 800 \text{ mm}^3$, and mice bearing bilateral PDX tumors with one tumor that reached 500 mm^3 , were randomized to treatment with drug/vehicle. Vinorelbine and paclitaxel solutions were purchased from the Dartmouth-Hitchcock Medical Center pharmacy. Eribulin was supplied by Eisai Pharmaceuticals, Inc. and solubilized in water. Solutions were protected from light and made fresh daily. Vinorelbine (7 mg/kg), paclitaxel (20 mg/kg), and eribulin (1.6 mg/kg) were administered by i.p. injection of 200 μL twice per wk for 2 weeks. In MMTV-PyMT mice, palpable tumors were surgically resected after a 1-wk drug holiday for downstream molecular analyses. In mice bearing bilateral orthotopic PDXs, one tumor was surgically after a 1-wk drug holiday for downstream molecular analyses. After a 2-week holiday in MMTV-PyMT mice, and when remaining PDX tumors resumed growth, mice were administered a second round of drug treatment for 2 weeks. In MMTV-PyMT mice, tissues were harvested after a 1-wk drug holiday following secondary drug treatment. In mice bearing PDXs, remaining tumors were surgically resected, and mice were maintained for 3 months prior to tissue harvest to assess metastasis.

MDA-MB-231/Luc-ZsGreen cells were injected i.v. via tail vein into NSG female mice at 8 weeks of age. Tumor burden was measured bioluminescence imaging. Mice were injected i.p. with 100 μL D-luciferin (2 mg/mL). After a 10-min uptake period, mice were imaged for bioluminescence using an IVIS Lumina III *In Vivo* Imaging System (PerkinElmer).

Immunofluorescence staining of tissue sections

Slide-mounted sections of FFPE tissue were deparaffinized using xylene and rehydrated through a graded ethanol series to water. Antigen retrieval was performed by incubation in sodium citrate buffer (pH 6.0) for 20 min in a pressure cooker, followed by 20 min of cooling at room temp. Sections were then incubated in blocking buffer (1% goat serum and 1% BSA in PBS) for 1 h at room temp. Slides were incubated at 4°C overnight with primary antibodies. After rinsing slides in TBST, slides were incubated in fluorophore-conjugated secondary antibodies (as above) and DAPI for 1 h at room temp. Slides were washed with TBST and mounted using Prolong Diamond Antifade mountant (ThermoFisher Scientific cat. #P36961). Tissues were imaged by fluorescence confocal microscopy.

Multiplexed Tyramide signal amplification (TSA) staining

Methodology was adapted from ref. ¹². PDX tumors were harvested from mice treated as indicated and FFPE. Five representative cores were selected from each specimen to make a tissue microarray. Human TNBC specimens were obtained from SOLTI-1007-NeoEribulin study¹¹ and Dartmouth-Hitchcock Medical Center pathology archives. Human FFPE diagnostic core biopsy specimens obtained at baseline were used directly for TSA staining. Human FFPE surgical tumor tissue specimens obtained after neoadjuvant chemotherapy were used to make a tissue microarray with 5 cores per specimen. Tissue sections were immunostained with antibodies targeting a panel of EMT markers: anti-Snail (Cell Signaling Technology cat. #3895, dilution 1:400); anti-KRT8 (Invitrogen cat. #PA5-29607, dilution 1:300); anti-KRT14 (Invitrogen cat. #MA5-11599, dilution 1:1000); anti-Vimentin (Cell Signaling Technology cat. #5741, dilution 1:500); anti-E-cadherin (BD Bioscience cat. #610182, dilution 1:500); anti-ZEB1 (Invitrogen cat. #PA5-82982, dilution 1:1000). The PerkinElmer OPAL Assay Development Guide was used to optimize antibodies and multiplexed staining procedures. Slides were microscopically scanned with the PerkinElmer Vectra 3 automated multispectral imaging system. Images were imported into InForm software (PerkinElmer), and analysis was performed per manufacturer's instructions and methods adapted from ref. ¹². Cells were phenotyped based on expression of one or multiple EMT markers (E-cadherin only; KRT8/E-cadherin; KRT14 only; KRT8/E-cadherin/vimentin; snail only; vimentin only; vimentin/ZEB1) and validated by marker distribution. Cell Mean Fluorescent units were extracted for each marker and normalized as a percentage of maximum and minimum fluorescence across all cells in all images. EMT was scored as in ref. ¹².

Lentivirus-mediated genetic barcoding of cells

PB3 cells (2×10^5) were seeded in a 6-cm dish and treated with 6 $\mu\text{g}/\text{mL}$ polybrene transfection reagent (Millipore cat. #TR-1003-G) for 1 h. A packaged lentiviral barcode library (CloneTracker XPTM 10M Barcode-3' Library with RFP-puro, Collecta cat. #BCXP10M3RP-V) was added onto cells at a multiplicity of infection of 0.5, and cells were incubated at 37°C for 24 h. Medium was refreshed and cells were maintained for 2 days. Cells were then trypsinized to obtain a single-cell suspension, and sorted by flow cytometry to collect the RFP-expressing subpopulation. RFP+ (barcoded) cells were re-plated and expanded for experimentation or archiving in liquid nitrogen.

Drug treatment of genetically barcoded cells

Since the 10x genomics platform could only analyze a maximum of 10^3 cells per sample, a founder population of 10^3 genetically barcoded PB3 cells was obtained to ensure consistency of barcode distribution across samples; this founder population was expanded for experimentation. Cells (8×10^5) were seeded into each well of a 12-well plate. The next day, cells were treated +/- 500 nM eribulin or 100 nM paclitaxel. Cells were incubated with drug for 72 h before drug washout. Cells were allowed to recover for 48 h, and then re-plated into 6-well plates to provide more surface area for expansion. Since cells seemed resistant to 100 nM paclitaxel, the dosage was increased to 250 nM for subsequent rounds of treatment. Drug treatments were repeated as above for 2-3 additional cycles, and a sampling of cells was removed and snap-frozen after each cycle.

Single-cell/single-nucleus RNA-seq and ATAC-seq of genetically barcoded cells

Cells were treated as indicated, trypsinized, washed in PBS with 0.04% BSA, and counted. Single-cell suspensions were processed using the 10x Genomics NextGen Single-Cell RNA-seq v3.1 and Single-Cell ATAC-seq v1 kits with or without multiplexing using lipid-oligo hashtags using manufacturer's instructions for nuclei isolation (scATAC), library preparation, and sequencing. Second batches of control-treated and eribulin-treated (Eri4) cells were analyzed on the 10x Genomics Multiome ATAC + Gene Expression assay. For retrieval of genetic barcodes, 10 μ L of amplified cDNA was used for 10 cycles of PCR using the 10x Genomics SI-PCR primer (5'AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGC*T*C) and BC_RPI_X_Fwd primer (CAAGCAGAAGACGGCATACGAGATNNNNNGTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACCGAACGCAACGCACGCA), where 'N' denotes sample-specific index sequences. Amplicons were purified with SPRI Select beads (Beckman Coulter), pooled with scRNA-seq libraries, and sequenced to a target depth of 5,000 reads/cell.

Genetic barcode whitelist preparation

We prepared a whitelist of barcodes by combining BC14 and BC30 (BC14sequence+BC30sequence) barcodes. In custom barcode-only sequencing, barcodes are expected in the following format: Custom barcode = 19bp constant + BC14 sequence + TGGT + BC30 sequence. We prepared barcodes in various formats as per the requirements of downstream tools using in-house scripts. The reference files play a crucial role in downstream analyses of custom barcodes FASTQ files by facilitating feature barcode demultiplexing.

Single-cell/single-nucleus RNA-seq data analysis

Eight libraries for single-cell/single-nuclei transcriptome data were obtained in 3 batches (Run1, Run2, Run3). Each batch contains samples from different treatments and dosages sequenced. While Run1 and Run2 data were from single-cell 3' V3 sequencing (scRNA) protocol, Run3 used the single-nuclei RNA+ATAC V1 sequencing (snRNA multiome) protocol. Hence, FASTQ and count matrix files were generated using 10x Genomics Cellranger-3.1.0, 10x Genomics Cellranger-4.0.0,⁵⁸ and 10x Genomics Cellranger-arc-1.0.0⁵⁹ for Run1, Run2, and Run3, respectively. Cellranger genome reference mm10 (mouse) was used as the reference for all runs. For Run1 and Run2, whitelist custom barcodes (described above) were used in Cellranger "--feature-ref" parameter for custom barcodes FASTQ. As Cellranger-arc pipeline doesn't support "--feature-ref" barcoding, custom barcode FASTQ files were processed using CITE-seq-Count v1.4.3 tool.

Count matrices were analyzed using the Seurat v3.1.4 pipeline.⁶⁰ Low-quality cells (<200 genes expressed; >50% UMIs in mitochondrial or ribosomal genes) were removed. Using selected variably expressing genes and significant principal components from PCA, clustering and UMAP projections were generated. All the samples were merged into one object to illustrate differences due to drug treatment and dosage. After merging, batch effects due to run and platform differences were regressed out. Pseudotime analysis was performed against the all-sample merged dataset using Monocle3 v0.2.1¹⁵⁻¹⁷ while considering "Untreated" cells as the root cells. To represent the relative frequency of each barcode over pseudotime, Muller plot representation was used.⁶¹ Relative frequencies were calculated as the ratio between number of cells associated with a barcode at a given pseudotime (binned) and the sum of all cells (from all barcodes) at the same pseudotime bin. Muller plot is accompanied with line chart illustrating the total number of cells at any given pseudotime.

Single-cell/single-nucleus ATAC-seq data analysis

Four libraries for single-cell/nucleus ATAC-seq data were obtained in 2 batches: Run1 with Run3 using scATAC V1 and snATAC (multiome) V1 protocols. FASTQ and peak count matrix files were generated using 10x Genomics Cellranger-atac-1.2.0 for Run1, and 10x Genomics Cellranger-arc-1.0.0 for Run3. Cellranger reference genome mm10 (mouse) was used as the reference. Custom barcode FASTQ files were processed using CITE-seq-Count v1.4.3 tool. Peak count matrices were analyzed using the Signac v1.1.1 pipeline. Low-quality cells (fragments in peak regions <1000 and >75000; percentage of UMIs in peaks >20%; ratio of UMIs in blacklist regions vs. peak regions >0.05; nucleosome signal >10; TSS enrichment <2) were removed. Using selected top features and 2-to-30 principal components from LSI, clustering and UMAP projection were generated. All samples were also integrated into one object using Harmony R package⁶² to illustrate differences due to drug treatment and dosage. In Harmony, batch effects due to run and technology differences were regressed out.

Integration and genetic barcode classification in single-cell/single-nucleus seq

To assign each cell to a genetic barcode, we applied the MULTISEQDemux method⁶³ from the Seurat pipeline. Though the method differentiated barcodes, this method was originally designed for demultiplexing samples where background estimation is appropriate for each cell from all barcodes. Herein, the enrichment level for each barcode could vary, and it was appropriate to calculate the background for each barcode from all cells. We deployed an in-house-developed R script using binomial distribution that estimates background for each barcode from all cells. We first annotated doublets (cells with ≥ 2 barcodes) and barcode-negative cells using MULTISEQDemux. Using this approach, we were able to re-annotate and increase the number of singlets (cells with 1 barcode), and remove doublets and barcode-negative cells. scRNA-seq and scATAC-seq datasets were then integrated with the TransferData module in the Seurat pipeline.

Selection vs. Induction identification by QISSMET: To identify and illustrate the cells that undergo bioinformatic Selection (i.e., drug-treated and untreated cells that cluster together) or Induction (i.e., drug-treated and untreated cells that clustering far apart), all cells in each barcode were analyzed using Jaccard index- and Euclidean distance-based methods. Euclidean distance was calculated between median points of cells from a sample per barcode in their UMAP space. For differences within samples, we used the Jaccard index method from `scclusteval v1.0`,⁶⁴ where cells of each barcode were re-clustered using a density clustering method (with same variable genes from original integrated dataset). Based on the number of cells for each sample in various clusters, the Jaccard index was calculated. In density clustering, proximal cells were assigned to one cluster. Therein, if all the cells are similar in a given scenario, then they will cluster closely and be assigned to one cluster.

QUANTIFICATION AND STATISTICAL ANALYSIS

Datasets were analyzed by unpaired *t*-test (for two-sample experiments) or multiple comparison-adjusted one-way ANOVA or two-way ANOVA with Tukey-adjusted posthoc pairwise comparisons according using Prism software (GraphPad).

Cell Reports Medicine, Volume 5







Supplemental information

**Pharmacological induction
of chromatin remodeling drives chemosensitization
in triple-negative breast cancer**

Meisam Bagheri, Gadisti Aisha Mohamed, Mohammed Ashick Mohamed Saleem, Nevena B. Ognjenovic, Hanxu Lu, Fred W. Kolling, Owen M. Wilkins, Subhadeep Das, Ian S. LaCroix, Shivashankar H. Nagaraj, Kristen E. Muller, Scott A. Gerber, Todd W. Miller, and Diwakar R. Pattabiraman


Uniprot protein name	Accession #	Hyperlink	delta-Sm
NFAC4_MOUSE	Q8K120	Q8K120	2.576
CARD9_MOUSE	A2AIV8	A2AIV8	2.463
CRNL1_MOUSE	P63154	P63154	2.352
BUB1_MOUSE	O08901	O08901	2.338
CDCA5_MOUSE	Q9CPY3	Q9CPY3	2.060
MK67I_MOUSE	Q91VE6	Q91VE6	1.827
DOCK6_MOUSE	Q8VDR9	Q8VDR9	1.824
SOSD1_MOUSE	Q9CQN4	Q9CQN4	1.810
FL2D_MOUSE	Q9ER69	Q9ER69	1.736
KI20A_MOUSE	P97329	P97329	1.715
CRIP3_MOUSE	Q6Q6R3	Q6Q6R3	1.671
CDNF_MOUSE	Q8CC36	Q8CC36	1.629
RGAP1_MOUSE	Q9WVM1	Q9WVM1	1.622
HNRL2_MOUSE	Q00PI9	Q00PI9	1.602
TOM22_MOUSE	Q9CPQ3	Q9CPQ3	1.552
MYO1H_MOUSE	Q9D6A1	Q9D6A1	1.494
MYO15_MOUSE	Q9QZZ4	Q9QZZ4	1.472
MYO7A_MOUSE	P97479	P97479	1.472
MYO7B_MOUSE	Q99MZ6	Q99MZ6	1.472
HNRPC_MOUSE	Q9Z204	Q9Z204	1.465
UB2E2_MOUSE	Q91W82	Q91W82	1.459
UB2E3_MOUSE	P52483	P52483	1.459
TERT_MOUSE	O70372	O70372	1.445
BAZ1B_MOUSE	Q9Z277	Q9Z277	1.433
PIMRE_MOUSE	Q8BFY7	Q8BFY7	1.420
MYO1D_MOUSE	Q5SYD0	Q5SYD0	1.352
H2A2B_MOUSE	Q64522	Q64522	1.327
RALY_MOUSE	Q64012	Q64012	1.311
SMRD1_MOUSE	Q61466	Q61466	1.309
SMRD3_MOUSE	Q6P9Z1	Q6P9Z1	1.309
RIOX1_MOUSE	Q9JF3	Q9JF3	1.290
EBP2_MOUSE	Q9D903	Q9D903	1.267
K1C19_MOUSE	P19001	P19001	1.081
CCNB1_MOUSE	P24860	P24860	1.030
CENPE_MOUSE	Q6RT24	Q6RT24	0.896
SOGA3_MOUSE	Q6NZL0	Q6NZL0	0.889
LEMD2_MOUSE	Q6DVA0	Q6DVA0	0.883
PERI_MOUSE	P15331	P15331	0.841
SRPRB_MOUSE	P47758	P47758	0.705
MUC2_MOUSE	Q80Z19	Q80Z19	0.580

Supplementary Table S1: Proteins with stability significantly altered by eribulin treatment in PB3 cells. Cells were treated +/- 300 nM eribulin for 4 h, and protein extracts were analyzed by PISA. Protein stability ratios vs. control are reported as delta-Sm values. The 40 proteins with delta-Sm >0.5 and p<0.05 are listed. Related to Figure 5.




Supplementary Figure S1: Eribulin induces MET in TNBC cells. (A) Flow cytometry-based quantification of EpCAM expression in PB3 parental cells and drug-resistant derivatives. (B/C) Estimation of EMT state of PB3 cells and drug-resistant derivatives by morphological assessment in brightfield images (B), and immunofluorescence for E-cadherin (green) and vimentin (white) (C). (D) A monolayer scratch assay was carried out in PB3 cells and drug-resistant derivatives to assess invasive properties over 16 h. (E) Dose-response curves of MDA-MB-231 cells were generated to calculate IC₅₀ values for eribulin, paclitaxel, and vinorelbine. (F/G) Estimation of EMT state of MDA-MB-231 cells and drug-resistant derivatives as in (B/C). (H) Estimation of EMT state of SUM159 cells and drug-resistant derivatives as in (B). (I) A monolayer scratch assay was carried out in MDA-MB-231 cells and drug-resistant derivatives to assess the invasive properties over 16 h. *p<0.05, ***p<0.0005, ****p<0.0001 by Tukey-adjusted pairwise comparison. (J) Flow cytometry-based quantification of CD104 and CD44 expression in MDA-MB-231 parental cells and drug-resistant derivatives. Related to Figure 1.

A Eribulin resistant: Induction
Barcode ID: bc14-29-bc30-49561




B Paclitaxel resistant: Selection
Barcode ID: bc14-6-bc30-93034




Barcode ID	Eribulin		Barcode ID	Paclitaxel	
	Euclidean distance	Jaccard Index		Euclidean distance	Jaccard Index
bc14-29-bc30-33048	Selection		bc14-4-bc30-67693	Selection	
bc14-43-bc30-75462	Undetermined	Induction	bc14-58-bc30-9763		
bc14-95-bc30-33662		Induction	bc14-65-bc30-62538		
bc14-6-bc30-93034		Selection	bc14-33-bc30-33994		
bc14-29-bc30-49561		Induction	bc14-29-bc30-33048		
bc14-71-bc30-88522	Induction		bc14-92-bc30-83570	Undetermined	Selection
bc14-69-bc30-34430	Induction		bc14-71-bc30-66188		Selection
bc14-51-bc30-38039	Induction		bc14-21-bc30-28628		Selection
bc14-51-bc30-21431	Induction		bc14-43-bc30-75462		Induction
bc14-13-bc30-72181	Induction		bc14-13-bc30-62836		Induction
bc14-76-bc30-49517	Induction		bc14-36-bc30-56638		Selection
bc14-92-bc30-83570	Induction		bc14-69-bc30-34430		Induction
bc14-1-bc30-96229	Induction		bc14-95-bc30-57159		Induction
bc14-55-bc30-99383		Induction	bc14-14-bc30-67938		Induction
bc14-39-bc30-41529	Induction		bc14-6-bc30-93034		Selection
bc14-97-bc30-52720			bc14-58-bc30-212		Selection
bc14-55-bc30-37135			bc14-18-bc30-19605		Selection
bc14-89-bc30-62622			bc14-38-bc30-7217		Induction
bc14-20-bc30-92761			bc14-2-bc30-46691		Selection
bc14-51-bc30-79562			bc14-50-bc30-60095		Induction
bc14-55-bc30-23349			bc14-51-bc30-21431		Induction
bc14-52-bc30-59099			bc14-76-bc30-49517		Selection
bc14-29-bc30-67687			bc14-36-bc30-3590		Induction
bc14-47-bc30-43673			bc14-2-bc30-62822		Selection
bc14-75-bc30-79440			bc14-29-bc30-67687		Induction
bc14-37-bc30-87265			bc14-22-bc30-18173		
bc14-95-bc30-65716			bc14-10-bc30-85109		
bc14-4-bc30-15682			bc14-55-bc30-99383		


D Differentially expressed genes: Eribulin




F scATAC-seq: Eribulin resistant (selection)



E Differentially expressed genes: Paclitaxel




G scATAC-seq: Eribulin resistant (induction)




Supplementary Figure S2: Clonal dynamics following drug treatment. (A/B) Representative plots of how the determination of selection vs. induction was made based on Jaccard Index. In (A), cells with a single genetic barcode are shown as an example. The representative plot (top) reveals a combination of induction and selection for this barcode: some clusters are resistant by induction (i.e., no untreated cells in the final treatment cluster), and other clusters are resistant by selection (i.e., at least one untreated cell in the ERI4 final treatment cluster). For reference, the inset shows the plot from all barcodes (reproduced from Figure 3B). The cluster with the largest number of drug-resistant cells was used to determine the mode of resistance for a given cell line/derivative. In this example, Cluster No. 1 (pink dots in lower right plot) has the largest number of ERI4 cells (pink dots in lower left plot), and these cells are resistant by induction; therefore, this barcode was assigned as resistant by induction. (B) Representative plots of barcodes resistant by selection. Untreated cells and PAC3 cells with the same barcode share the same clusters as observed by the Jaccard index score. (C) Levels of induction or selection were determined by breakdown of both Euclidean distance and Jaccard index calculations. Representative data are shown. (D/E) Volcano plots showing differentially expressed genes that may predict induction or selection


resistance upon eribulin (D) and paclitaxel (E) treatment. Gene expression profiles of (i) untreated cells with the same barcode as eribulin induction-resistant cells and paclitaxel induction-resistant cells (highest 10 Euclidean distance values) were compared against (ii) untreated cells with the same barcode as eribulin selection-resistant and paclitaxel selection-resistant cells (lowest 10 Euclidean distance values). Significant genes were determined by FDR <0.05 and fold-change >2. **(F/G)** scATAC-seq UMAP projection of (F) untreated and eribulin-resistant cells by selection, and (G) untreated and eribulin-resistant cells resistant by induction (highest 10 Euclidean distance values). Related to Figure 3.



Supplementary Figure S3: Eribulin induces a shift in chromatin profile of TNBC cells. (A) Principal Components Analysis (PCA) of the 500 most variably expressed genes between PB3 parental and drug-resistant cells analyzed by bulk RNA-seq. (B) Immunoblotting of lysates from SUM159 parental and drug-resistant cells. (C-E) Bulk ATAC-seq was performed using PB3 parental and drug-resistant cells. Differences in chromatin accessibility are depicted as a heat map of the most variable peaks (C), and peak accessibility surrounding consensus distal-associated regions (D). Panel (E) shows transcription factor (TF) motifs (de-)enriched in PB3^{ERI-R} cells. (Left) The x-axis shows target gene expression, and the y-axis shows $-\log_{10}(\text{p-value})$ of each TF. (Right) TF motif enrichment over target expression. Circle size indicates p-value, and circle color indicates percentile expression of target genes. (F) Advanced volcano plot of active and inactive TFs determined by diffTF from ATAC-seq. TF classification is displayed as circle color, and number of TF binding sites used to determine TF activity is displayed as circle size. Related to Figure 4.




Supplementary Figure S4: ZEB1-SWI/SNF interactions are necessary for maintenance of a mesenchymal state. (A) Proteome Integral Solubility Alteration (PISA) assay of PB3 cells treated +/- 300 nM eribulin for 4 h to explore protein targets of eribulin. Proteins with $DSm > 0.5$ and $p < 0.05$ (t-test) compared to control were prioritized. (B) Estimation of EMT state by morphological assessment of brightfield images of PB3 cells with knockout of *Smarcd1*, *Smarcd3*, *Smarcd1/2/3*, or scrambled control. (C) Immunoblot validation of CRISPR/Cas9-mediated knockout of *Smarcd1* in PB3 cells using 3 different sgRNAs (a, b, c). The right lane provides confirmation of overexpression of exogenous *Smarcd1*. (D) Immunoblot analysis of EMT markers in MDA-MB-231 cells with knockout of *SMARCD1*, *SMARCD3*, or *SMARCD1/2/3*. (E) Immunoblot validation of CRISPR/Cas9-mediated knockout of *SMARCD1* or *SMARCD3* in MDA-MB-231 cells using 3 different sgRNAs (a, b, c). (F) Immunoblot analysis of PB3 parental and ERI-R cells with knockout (KO) or overexpression (OE) of *Smarcd1*. Drug was withdrawn at least 72 h prior to seeding for assay. (G) Cells were treated +/- eribulin for 48 h, and lysates were analyzed by immunoblot. (H) MDA-MB-231 cells were treated +/- eribulin for 48 h. Lysates and immunoprecipitates (anti-ZEB1, anti-SMARCC1, or IgG control) were analyzed by immunoblot. (I-K) Genome-wide occupancy of ZEB1 binding sites in MDA-MB-231 cells treated with eribulin for 0, 24, 48, or 72 h was determined by CUT&RUN. Shown in (I) are the average CUT&RUN enrichment profile (top) and heatmap illustrating the CUT&RUN signal +/- 2 kb of peaks (bottom). UpSet plots of differentially accessible peaks at the indicated time points are shown in (J). Panel (K) shows signal tracks of Zeb1 target gene chromatin accessibility. Related to Figure 5.




Supplementary Figure S5: Primary eribulin treatment sensitizes TNBC cells to other chemotherapeutics. (A) PB3 cells were analyzed using senescence-associated beta-galactosidase assay (top flow cytometry panel) and SYTOX for live/dead/apoptotic cells (lower flow cytometry panel). (B-D) PB3^{ERI-R} cells were treated +/- paclitaxel or vinorelbine. PB3^{PAC-R} cells were treated +/- eribulin or vinorelbine. PB3^{VIN-R} cells were treated +/- paclitaxel or eribulin. After 48 h, cells were analyzed as in (A). (E) Senescence-associated beta-galactosidase assay was used to analyze MDA-MB-231^{ERI-R}, MDA-MB-231^{PAC-R}, and MDA-MB-231^{VIN-R} cells as in (A). Related to Figure 6.


A.




B.




C.




D.



E.



F.




G.


NCI-140 Metastasis

Group	Lung	Liver	Ovary	lymph node
Control	1/5	0/5	5/5	1/5
E1P2	0/5	0/5	0/5	0/5
E1V2	0/5	0/5	0/5	0/5
P1E2	0/5	0/5	1/5	0/5
V1E2	0/5	0/5	1/5	0/5


H.




I.



J.



K.




L.


JAX-91

Group	Lung	Liver	Ovary	lymph node
Control	0/0	3/5	4/5	4/5
E1P2	0/0	0/0	1/5	2/5
E1V2	0/0	0/0	0/0	1/5
P1E2	0/0	0/0	4/5	4/5
V1E2	0/0	0/0	2/5	2/5

M.



Supplementary Figure S6: MET induction is accompanied by robust tumor regression and reduced metastatic burden. (A) H&E histology of representative MMTV-PyMT tumors harvested after 2 wk of treatment followed by a 1-wk drug holiday. **(B)** Mice bearing orthotopic NCI-140^{naive} tumors were treated with single agents as indicated. Tumor volumes are shown as mean of 10 tumors +/- SD. **(C)** H&E histology of JAX-98^{naive} tumors harvested from mice treated as a (A). **(D)** H&E histology of NCI-140^{naive} tumors harvested from mice treated as a (A). **(E)** NCI-140^{naive} tumors harvested from mice treated as in (A) were used for immunofluorescence for E-cadherin (green) and vimentin (red). **(F)** Mice bearing bilaterally-implanted orthotopic NCI-140^{naive} tumors were treated with paclitaxel, eribulin, or vinorelbine for 2 wk followed by a 1-week holiday. One tumor was surgically resected, and mice were maintained until the remaining tumor resumed growth. Mice were then treated with a different drug as indicated. Tumor volumes were analyzed as in (B) and are shown as mean of 5 tumors +/- SD. **(G)** In mice with NCI-140^{naive} xenografts treated as in (F), after the secondary drug treatment the remaining tumor was surgically resected. Mice were then maintained for 3 months before organs were harvested for evaluation of metastasis. Distribution patterns of metastasis are noted. **(H)** H&E histology of NCCC-470^{NAC} tumors harvested from mice treated as a (A). **(I)** Mice bearing orthotopic JAX-91^{NAC} tumors were treated with single agents as indicated and analyzed as in (B). **(J)** H&E histology of JAX-91^{NAC} tumors harvested from mice as in (C). **(K)** JAX-91^{NAC} tumors harvested from mice treated as in (A) were used for immunofluorescence as in (E). **(L-M)** Mice bearing bilaterally-implanted JAX-91^{NAC} tumors were treated and analyzed as in (F/G). Panel (M) shows tumor volumes as mean of 5 +/- SD. *p<0.05, **p<0.001, ***p<0.0005, ****p<0.0001 by Tukey-adjusted pairwise comparison. Related to Figure 7.



Supplementary Figure S7: Eribulin reverses EMT in PDX tumors. (A/B) Representative images of multiplexed immunostaining of EMT markers in PDX tumors from mice treated as indicated. (C-F) EMT scores were generated using images as in (A/B) from 5 tumors per group and ≥ 100 microscopic fields/tumor. Each histogram reflects scores from ≥ 500 fields. (G-J) inForm image analysis was used to quantify proportions of cancer and stromal cells within tumor sections processed as above. * $p < 0.05$, ** $p < 0.001$, *** $p < 0.0005$, **** $p < 0.0001$ by Tukey-adjusted pairwise comparison.